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Peroxisome proliferator-activated receptor (PPAR)α, β (also known as δ), and γ function as sensors for fatty acids and fatty acid
derivatives and control important metabolic pathways involved in the maintenance of energy balance. PPARs also regulate other
diverse biological processes such as development, diﬀerentiation, inﬂammation, and neoplasia. In the nucleus, PPARs exist as
heterodimers with retinoid X receptor-α bound to DNA with corepressor molecules. Upon ligand activation, PPARs undergo
conformational changes that facilitate the dissociation of corepressor molecules and invoke a spatiotemporally orchestrated
recruitment of transcription cofactors including coactivators and coactivator-associated proteins. While a given nuclear receptor
regulates the expression of a prescribed set of target genes, coactivators are likely to inﬂuence the functioning of many regulators
and thus aﬀect the transcription of many genes. Evidence suggests that some of the coactivators such as PPAR-binding protein
(PBP/PPARBP), thyroid hormone receptor-associated protein 220 (TRAP220), and mediator complex subunit 1 (MED1) may
exert a broader inﬂuence on the functions of several nuclear receptors and their target genes. Investigations into the role of
coactivators in the function of PPARs should strengthen our understanding of the complexities of metabolic diseases associated
with energy metabolism.
1.Introduction
The foundation for the discovery and designation of the
PPAR subfamily of nuclear receptors in the early 1990s is
the cumulative work over the preceding 25 years with per-
oxisome proliferators, a group of structurally diverse chem-
icals that induce characteristic and predictable pleiotropic
responses including the transcriptional activation of genes
involved in the fatty acid oxidation [1–6]. The PPAR sub-
family consists of three members namely PPARα (NR1C1),
PPARβ (also known as δ) (NR1C2), and PPARγ (NR1C3)
with a high degree of sequence conservation across the
species [1, 2, 7–9]. All three PPARs in the human and
mouse are encoded by separate genes that are on diﬀerent
chromosomes [9]. PPARγ has two isoforms, PPARγ1, and
an N-terminal 30 amino acid extended form PPARγ2, both
encoded by the same gene using two distinct promoters
and alternate splicing [10, 11]. All three members of PPAR
subfamily function as sensors for fatty acids and fatty
acid derivatives and control metabolic pathways involved
in energy homeostasis [12, 13]. PPARs display high levels
of homologies at the protein level, but exhibit distinct and
noninterchangeable functional roles in mammalian energy
metabolism [9]. PPARα is expressed in tissues with high
fatty acid oxidation activities, which include liver, kidney,
small intestine, heart, and skeletal muscle, consistent with its
predominant functional role in regulating lipid catabolism.
In the liver, PPARα is the master regulator of mitochondrial,
peroxisomal, and microsomal fatty acid oxidation systems
where it is activated by synthetic peroxisome proliferators
and in addition senses the inﬂux of fatty acids during fasting
to upregulate the fatty acid burning capacity [14]. PPARα
also plays a role in lipoprotein synthesis, inﬂammatory
responses and the development of cancer in the rodent liver
[15–19]. PPARβ is ubiquitously expressed with relatively
higher levels found in brain, adipose tissue, and skin
[20]. Activation of PPARβ also induces expression of genes
required for fatty acid oxidation and energy dissipation2 PPAR Research
in skeletal muscle and adipose tissue which in turn lead
to improved lipid proﬁles and reduced adiposity [21]. In
the liver, PPARβ can be activated by plasma free fatty
acids inﬂuxed during fasting conditions [22]. PPARγ which
is expressed at a relatively high level in adipose tissue
serves as an essential regulator for adipocyte diﬀerentiation
and promotes lipid/energy storage in mature adipocytes by
increasing the expression of several key genes in this pathway
[23]. These two important functions of PPARγ,n a m e l y
adipogenesis and fat storage in adipocytes account for the
insulin sensitizing eﬀects of the anti-diabetic thiazolidine-
diones [24]. In summary, PPARα and PPARβ participate
in energy burning, whereas PPARγ is critical in regulating
adipocyte diﬀerentiation and energy storage by adipocytes
[11, 25, 26].
2.TranscriptionalRegulation of PPARs
PPARs are ligand-activated transcription factors similar to
other members of the nuclear hormone receptor superfamily
[7, 8]. PPARs are nuclear in location, where they remain
heterodimerized with the 9-cis retinoic acid receptor, RXRα
(NR2B) [13] and bind to the upstream cis-acting regulatory
regions termed as peroxisome proliferator response element
(PPRE) of target genes [9, 27]. The canonical PPRE con-
sists of two direct repeats AGGTCA separated by a single
nucleotide so-called DR-1 element [28]. The two half-sites
are distinguishable by their 5  and 3  positioning on the DR1
element whereby the DNA binding domain of PPAR binds
5  half-site while RXR binds to the 3  half-site [29, 30]. In
addition to core DR-1 sequence, PPRE element contains an
additional AAACT motif at the 5  upstream region [30]. The
hinge region of PPAR forms extensive interaction with the
upstream AAACT element [30]. In the absence of ligand, the
unliganded PPAR-RXR heterodimer remains bound to the
nuclear receptor corepressor (NCoR) and silencing mediator
of retinoid and thyroid hormone receptor (SMRT), two
well-characterized corepressors (Figure 1) that are mostly
present in the corepressor complex [31]. Both NCoR and
SMRT directly interact with the Sin3 complex to form
a multisubunit repressor complex [32]. SMRT functions
as a platform protein and facilitates the recruitment of
histone deacetylases (HDACs) to the DNA promoters bound
by speciﬁc interacting transcription factors [32]. Another
corepressor, Receptor Interacting Protein 140 (RIP140) also
known as NRIP1 (nuclear receptor interacting protein 1)
directly recruits HDAC and represses the activity of various
nuclear receptor including PPARs by competing with their
coactivators [33–35]. In the absence of ligand activation
of nuclear receptor, the corepressor protein complex is
known to subdue target gene transcription by causing the
deacetylation of histones [31].
The nuclear receptor-regulated transcriptional activation
of target genes depends on the binding of a cognate
ligand to the receptor (activator). For example, activation
of PPARα-RXR heterodimer by a PPARα ligand triggers
conformational changes in the receptor which releases the
corepressor complex and recruits cofactor complexes to the
promoter region of target genes (Figure 1) to initiate tran-
scription [38, 39]. Transcription coactivators increase gene
transcription via the acetylation of histones and through
the recruitment and stabilization of the transcriptional
complexes, mainly the Mediator complex which interacts
directly with activator proteins and pol II [40–42]. During
the past 15 years, more than 300 cofactors (coactivators,
coregulators, corepressors etc.) have been identiﬁed but the
in vivo physiological regulatory functions of many of these
moleculesinreceptor/gene/cell-speciﬁctranscriptionremain
to be explored [43]. This paper summarizes the current
state of knowledge about the roles of coactivators and coac-
tivator associated proteins (Table 1), with special emphasis
on p160/SRC family members and PPAR-binding protein
(PBP/PPARBP)/thyroid hormone receptor-associated pro-
tein 220 (TRAP220)/mediator complex subunit 1 (Med1), in
the functioning of PPARs.
3. Coactivators for PPAR Function
Transcriptional activation of PPAR-regulated genes is
enhanced by coactivators. Most coactivators possess one
or more LXXLL motifs (L: leucine and X: any amino
acid) some of which may make contact with a coactivator-
binding groove in the ligand-binding domain of nuclear
receptor [44]. The assembly or preassembled coactivator
complexes facilitate the liganded PPAR to achieve transcrip-
tional activation of speciﬁc target genes in a tissue/cell-
speciﬁc manner [45, 46]. Once coactivators are recruited to a
liganded nuclear receptor they remodel chromatin structure
by the intrinsic histone acetyltransferase (HAT) or methyl
transferase activities [46]. In order to achieve this, steroid
receptor coactivator (p160/SRC) family of proteins, which
possess HAT activity, are recruited to the activation function
2 (AF-2) domain of the nuclear receptor and complex with
the universal coactivator cyclic-AMP responsive element
binding protein (CREB)-binding protein (CBP) and its
homologue p300 [47–49]. CBP and p300 also exhibit potent
HAT activity [50].
The second category of coactivators, with no known
enzymatic functions, participates in the formation of a
well-known multisubunit protein complex, variously called
TRAP/DRIP/ARC/Mediator complex, consisting of 15–30
proteins [36, 37, 41, 57, 73–77]. Mediator complex, which
is anchored by PBP (PPARBP)/TRAP220/DRIP205/Med1
facilitates interaction with poll II of the basal transcription
machinery [41, 73, 75]. Members of this Mediator complex
appear to be devoid of intrinsic enzymatic activities [46],
but play an important role in connecting CBP/p300 bound
coactivators with pol II containing preinitation complex
[76]. Disruption of CBP/p300 and Med1 genes in the mouse
results in embryonic lethality around E11.5 days, indicating
that deletion of these pivotal anchoring coactivators aﬀects
the integrity of the cofactor complexes, thus altering the
function of many nuclear receptors and most likely of other
transcription factors [77–79].
An u m b e ro fo t h e rc o a c t i v a t o r sa n dc o a c t i v a t o r -
associated proteins that possess enzymatic activities likePPAR Research 3
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Figure 1: A schematic representation of ligand-dependent recruitment of coactivators for PPAR-regulated target gene transcription. In the
absence of ligand, the PPAR-RXR heterodimer recruits corepressors, which in turn, assemble additional components of a repressor complex
including histone deacetylase (HDAC). When ligand (yellow trapezium representing PPAR ligand, and blue trapezium representing 9-cis-
retinoicacidas RXRligand) binds,conformational changes inPPAR-RXRinduce dissociation ofcorepressor complex. Active transcriptional
complex assembles with coactivator proteins either sequentially or preassembled subcomplex modules. PPAR binds to peroxisome
proliferator response element (PPRE) and assemble coactivator complexes that acetylate (SRCs, p300) or methylate (CARM1) nucleosomes
for chromatin remodeling. Mediator components [36, 37] contact PPARs and facilitate the recruitment of the basal transcription machinery
(TATA-box-binding protein [TBP]/TBP-associated factors [TAFs]) to form linkage with RNA polymerase II for transcription of speciﬁc
target genes.
Table 1: Some known coactivator and coactivator associated proteins that regulate PPAR function.
Coactivator proteins Enzyme activity Function References
SRC-1/NCoA-1 HAT Histone acetylation [51, 52]
SRC-2/TIF2/GRIP1 HAT Histone acetylation [53]
SRC3/pCIP/AIB1 HAT Histone acetylation [54, 55]
CBP/p300 HAT Histone acetylation followed by recruitment of p160/SRCs [56]
MED1/TRAP220/PBP None Anchor for Mediator complex [57, 58]
PGC-1α None Recruit coactivator with HAT activities [59]
PGC-1β/PERC None Recruit coactivator with HAT activities [60]
PRIP/NCoA6 None Recruit ASC complex [61, 62]
PRIC285 Helicase Chromatin remodeling by histone displacement and nucleosomal
sliding
[63]
PRIC320/CHD9 Helicase Chromatin remodeling by histone displacement and nucleosomal
sliding
[64]
SWI/SNF ATPase ATP dependent mobilization of nucleosome [65, 66]
BAF60a/SMARCD1 None Recruit SWI/SNF complex [67, 68]
BAF60c/SMARCD3 None Recruit SWI/SNF complex [69]
Coactivator-associated proteins
PIMT/NCoA6IP Methyltransferase Methylation of caps of snRNAs and snoRNAs [70]
CARM1/PRMT4 Methyltransferase Potentiate SRCs by methylation of Histone H3 [71]
CoAA None RNA splicing [72]4 PPAR Research
methyltransferase (CARM1) [71], helicase (PRIC285, p68)
[63, 80], and ATP dependent chromatin remodeling
properties (PRIC320, SWI/SNF) [63, 80] or those with-
o u ta n ye n z y m a t i ca c t i v i t i e ss u c ha sP P A R γ coactivator-
1α (PGC-1α), PGC-1β,a n dB A F s[ 81, 82]h a v eb e e n
identiﬁed in the active PPAR transcriptional complex,
referred to as PRIC (PPARα-receptor interacting cofac-
tor) complex [64, 80]. Some other important coactivators
such as PRIP (peroxisome proliferator-activated receptor-
interacting protein)/ASC2/AIB3/RAP250/NCoA6 [61, 83–
85] and PIMT (PRIP-interacting protein with methyl-
transferase domain/NCoA6IP) [70] are also identiﬁed,
which serve as linkers between the initial HAT complex
of CBP/p300 and p160 coactivators and the downstream
mediator complex [76]. CCPG (constitutive coactivator of
PPARγ)isidentiﬁedasanovelcoactivatorforPPARγ [86].As
mentioned above, sequential or combinatorial recruitment
of various multisubunit coactivator proteins on the liganded
nuclear receptor leads to the establishment of a stable
preinitiation complex with multiple possible conﬁgurations
on to the target gene promoter.
4. p160/SRC Familyof Coactivatorswith
HATActivity
p160/SRC family of coactivators consists of three mem-
bers, namely, SRC-1/NCoA-1, SRC-2/TIF2 (transcriptional
intermediary factor2)/GRIP1(glucocorticoidreceptorinter-
acting protein 1), and SRC-3/pCIP (CBP-interacting pro-
tein)/RAC3 (receptor-associated coactivator-3)/ACTR/AIB1
(ampliﬁed in breast cancer-1)/TRAM-1(thyroid hormone
receptor activator molecule 1) [51–55]. These proteins
are required for mediating the transcriptional function of
nuclear receptors and other transcription factors in a ligand-
dependent manner [87, 88]. All three p160/SRC family
members contain bHLH and PAS domains, which are
involved in protein-protein interactions. These coactivators
also contain three LXXLL motifs, that mediate recognition
of, and binding to AF-2 region of a variety of nuclear
receptors [89]. They possess HAT activity and are part of
the ﬁrst multiprotein coactivator complex with CBP/p300
on DNA bound-liganded nuclear receptors and participate
in the acetylation of histones and remodel chromatin
structure to unravel DNA for transcription [76, 88]. SRC-
1 interacts with many nuclear receptors including PPARγ
and PPARα, and the X-ray crystal structure of SRC-1
and the liganded PPARγ complex revealed that binding
is between highly conserved glutamate and lysine residues
in the PPARγ ligand binding domain and the backbone
atoms of the LXXLL helices of SRC-1 [29]. Protein-protein
interactions between PPARα and SRC-1 and SRC-3 have
beendocumentedandtheseinteractionsappearstobeligand
independent [52, 54]. p160/SRC family members exhibit
strong sequence homology and somewhat similar functions
under in vitro transactivation conditions. But gene knockout
mouse models have provided valuable insights into the in
vivo functional properties of these molecules [75, 88]. These
mouse models include SRC-1−/−,S R C - 2 −/− and SRC-3−/
single gene disruptions and SRC-1−/−/SRC-2−/− and SRC-
1−/−/SRC-3−/− double nulls [50, 90–95].
Mice lacking SRC-1 were generated to delineate its role
in estrogen receptor, progesterone receptor, and PPARα
signaling [90, 92]. SRC-1 null mice are viable and fertile but
show somewhat subdued response to sex hormonal stimuli
after orchiectomy or ovariectomy [90, 96]. However, SRC-
1−/− mice when challenged with PPARα ligands, such as
Wy-14,643 or ciproﬁbrate, display the characteristic robust
pleiotropic responses, including hepatomegaly, hepatic per-
oxisome proliferation and PPARα-target gene activation
[92]. These responses appear essentially similar to those
exhibited by SRC-1+/+ littermates indicating that SRC-1 is
not essential for PPARα signaling in liver [92]. Likewise, as
shown here, studies with SRC-2 and SRC-3 null mice also
revealed that PPARα target gene activation in liver is not
dependent on these coactivators. Hepatic responses of SRC-
1, SRC-2 and SRC-3 null mice following Wy-14,643 admin-
istration appear similar to those of wild-type mice treated
with a PPARα ligand (Figure 2). Histological evaluation of
liver sections, processed to visualize peroxisomal catalase,
show similar increases in the number of peroxisomes in
hepatic parenchymal cells of wild-type and SRC null mice
treated with a peroxisome proliferator (Figures 2(a)–2(h)).
To further investigate the inﬂuence of SRC family on
PPARα function, we evaluated the changes in fatty acid-
metabolizing enzymes in the liver of SRCs null and wild-
type mice by Northern and Western blot analyses (Figures
2(i) and 2(j)). Northern blot analysis of total liver RNA
shows similar basal levels of peroxisomal fatty acyl-CoA oxi-
dase 1 (ACOX1), enoyl-CoA hydratase/L-3hydroxyacyl-CoA
dehydrogenase bifunctional protein (L-PBE), peroxisomal 3-
ketoacyl-CoA thiolase (PTL), and microsomal cytochrome
P450 fatty acid ω-hydroxylase CYP4A1 in the livers of both
wild-type and SRC-1, -2 and -3 null mice (Figure 2(i)).
Massive increases in hepatic mRNA levels of these enzymes
w e r en o t e di na l lS R Cn u l lm i c et r e a t e dw i t haP P A R α ligand
(Figure 2(i)). The increases appear similar to that noted in
the livers of Wy-14,643 treated wild-type mice (Figure 2(i)).
Western blot analysis reveals increases in the content of
fatty acid oxidation enzyme proteins in liver of intact and
S R Cn u l lm i c e( Figure 2(j)). The expression levels of hepatic
peroxisomal fatty acid β-oxidation enzymes ACOX1, L-
PBE, D-PBE, PTL, and SCPx (sterol carrier protein x) were
increased signiﬁcantly after Wy-14,643 administration in
both wild-type and SRC-1, -2, and -3 null mice (Figure 2(j)).
Furthermore, no signiﬁcant diﬀerences in the magnitude
of increases are observed in hepatic mitochondrial enzymes
short-chain acyl-CoA dehydrogenase (SCAD), medium-
chain acyl-CoA dehydrogenase (MCAD), and long-chain
acyl-CoA dehydrogenase (LCAD) among wild-type and
SRCs null treated mice (Figure 2(j)). Together, these data
indicate that no member of p160/SRC family of coactivators
(SRC-1, SRC-2 and SRC-3) is required for PPARα-mediated
transcriptional activation in vivo [90].
Although the single gene-knockout mice have demon-
strated that loss of individual members of p160/SRC family
of coactivators is redundant for PPARα function in liver,
it remains to be ascertained if deletion of two or all threePPAR Research 5
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Figure 2: (a–h) Peroxisome proliferation in liver cells of wild-type (WT), SRC-1−/− SRC-2−/− and SRC-3−/− mice treated with Wy-14,643
for 4 days. Liver sections were processed for the cytochemical localization of peroxisomal catalase by using alkaline 3 ,3 -diaminobenzidine
substrate. Control diet (upper panels; a, c, e, g). Wy-14,643 diet (lower panels; b, d, f, h). Peroxisomes appear as brown dots (arrows)
distributed throughout the cytoplasm in these 0.5μm thick sections. All mice, wild-type and SRC nulls displayed extensive peroxisome
proliferation after treatment with Wy-14, 643 indicating that these coactivators are not required for PPARα-regulated pleiotropic responses
including fatty acid oxidation. (i) Northern blot analysis to conﬁrm changes in mRNA expression of peroxisomal and microsomal fatty
acid metabolizing enzymes in wild-type and SRC nulls after 4-days treatment with PPARα ligand Wy-14, 643. All genes are regulated by
PPARα. Fatty acyl-CoA oxidase-1 (ACOX1), peroxisomal enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase bifunctional enzyme (L-
PBE), and peroxisomal thiolase (PTL) represent peroxisomal β-oxidation system while CYP4A1 is involved in microsomal ω-oxidation of
fatty acids. GAPDH is used as an indicator of RNA loading. (j) Western blot analysis from the above-mentioned livers was used to verify
the degree of expression of peroxisomal and mitochondrial fatty acid metabolizing enzymes in wild-type and SRC knockout mice. Liver
homogenates (20μg) from each group of mice were run on 4–20% SDS PAGE gel and immunoblotted using antibodies for peroxisomal
(ACOX1, L-PBE, PTL, D-PBE, and SCPx) and mitochondrial (SCAD, MCAD, and VLCAD) fatty acid metabolizing enzymes. No diﬀerence
in the induction was observed between SRC nulls and wild-type for the β-oxidation enzymes.
of these coactivators aﬀects the PPARα signaling. SRC-1
is required for the assembly of a complex that includes
CBP/p300 for enhancing the coactivator function of PPARγ
coactivator-1 (PGC-1) [95]. It appears that the docking of
PGC-1 to PPARγ stimulates an apparent conformational
change in PGC-1 that permits binding of SRC-1 and
CBP/p300, resulting in a large increase in transcriptional
activity, and this transcriptional enhancement function of
PGC-1 fails to manifest in SRC-1 null cells [97]. SRC-1 null
mice exhibit partial impairment of PPARγ function with
decreased PGC-1 regulated thermogenic activity in brown
adipose tissue [95]. The lower energy expenditure in SRC-
1 null mice predisposes to higher sensitivity to obesity upon
highfatfeeding[88,95,98].Fattyacidoxidationinbrownfat
isalsodecreasedduetopartialimpairmentofPPARγ/PPARα
function in the absence of SRC-1.
SRC-2 has been implicated in a broader range of
physiological processes including reproduction, mammary6 PPAR Research
morphogenesis, uterine function and energy metabolism by
aﬀectingtheregulationofadaptivethermogenesis[99].SRC-
2 null mice are viable, but the fertility of both sexes is
impaired [94, 100]. These mice are resistant to diet-induced
obesityanddisplayedenhancedadaptivethermogenesis[95].
In white adipose tissue, disruption of SRC-2 increases leptin
expression as well as that of genes involved in lipolysis.
Additionally, these mice manifest a decreased potential for
fatty acid storage [95, 101]. Disruption of SRC-2 gene in
the mouse reduces PPARγ function in white adipose tissue
resulting in a lesser degree of fat accumulation [76, 95]. This
enhances the function and development of brown adipose
tissue, leading to increased levels of uncoupling protein 1,
PGC 1α and ACOX1, promoting energy expenditure [76, 87,
95]. Gene knockout studies have demonstrated that SRC-
3 is required for normal growth, puberty and mammary
gland development [93]. SRC-3 null mice also show reduced
body weight and adipose tissue mass with a signiﬁcant
decrease in PPARγ expression. At molecular level, SRC-
3 interacts with the transcription factor CAAT/enchancer-
binding protein(C/EBP) to control gene expression through
PPARγ. These results imply that SRC-3 exerts a key role in
adipocyte diﬀerentiation in vitro and in vivo, and that this
regulation of adipogenesis is upstream of PPARγ [101, 102].
SRC-3geneisoftenampliﬁedoroverexpressedinmanytypes
of cancers [93, 94].
The redundancy of p160/SRC family of coactivators in
the energy balance or expenditure function of PPARs noted
in SRC single-knockout mice suggests the existence of possi-
ble cooperative eﬀects among the three members of the SRC
family. To illuminate the physiological functions aﬀected
by double deletion of these coactivators, mice deﬁcient in
both SRC-1 and SRC-2 [100], or deﬁcient in both SRC-1
and SRC-3 [50] have been generated. Most SRC-1/SRC-2
double null mice die at birth, generally before the weaning
stage [100]. SRC-2−/− mice are protected against obesity and
display enhanced adaptive thermogenesis, whereas SRC-1−/−
micearepronetoobesityduetoreducedenergyexpenditure.
Together, these two members of SRC family control energy
balance between white and brown adipose tissues through
regulating PPARγ activity [101].
Most SRC-1 and SRC-3 double null mice also die
before birth and surviving combined-knockout mice are
lean and resistant to high-fat diet induced obesity [50].
These mice exhibit a developmental arrest in interscapular
brown adipose tissue and defective thermogenesis due to a
deﬁciency in the regulation of selective PPARγ target genes
involved in adipogenesis and mitochondrial uncoupling. It is
of interest that these double null mice consume more food
because of lower leptin levels, but remain lean mostly due to
a higher basal metabolic rate and enhanced physical activity
[50]. Taken together, SRC-1 and SRC-3 play critical roles in
energy balance by mediating both energy intake and energy
expenditure [75].
To investigate the changes in gene expression proﬁles,
microarray analysis has been used with the RNA from livers
of SRC-1, SRC-2, and SRC-3 single null animals [98]. The
overall pattern of altered hepatic gene expression in the
SRC-1 null mice was one of upregulation as compared
to wild-type mice. SRC-2 null mice appeared an overall
downregulation compared to wild-type mice. In SRC-3
deﬁcient mice, a minimal change of gene expression in
liver was observed. All these data suggest that changes
in gene expression for each SRC member show speciﬁc
and nonoverlapping expression patterns and that the three
members of SRC family play a key role in coregulating
energy homeostasis and obesity [76, 98]. It is clear from
experimentsinmicethatallthreemembersoftheSRCfamily
contain both redundant and distinct functions and that each
individual SRC contains the capacity to regulate diﬀerent
biological functions [53].
5.CBP/p300 withHAT Activity
CBP and p300, generally referred to as CBP/p300, are
universal coactivators that link transcriptional activators to
the basal transcription apparatus and provide a scaﬀold
to integrate multiple cofactors. CBP was ﬁrst identiﬁed
as a protein that binds CREB (cAMP response element-
binding protein), whereas p300 was cloned as an adenovirus
oncoproteinE1A-associatedprotein[56].Subsequentstudies
established that CBP and p300 are signiﬁcantly related and
that human CBP resembles the human p300 more closely
[103, 104]. These proteins are well conserved amongst
mammals and homologs of CBP/p300 have been found in
Drosophila, Caenorhabditis elegans,a n dArabidopsis thaliana
[105]. No CBP/p300 homologs are found in prokaryotes
or yeast [104]. CBP/p300 proteins possess HAT activity
and the HAT domain has the ability to recruit other
proteins such as p160/SRC family members with HAT
activity to further enhance the acetylation potential of the
coactivator complex to remodel chromatin structure for
eﬃcient gene transcription [76, 106–108]. CBP/p300 pro-
teins share several conserved regions, which constitute most
of their known functional domains such as bromodomain
[109], cysteine/histidine-rich domains, a KIX domain to
which transcription factor CREB binds, glutamine- and
proline-richdomain,receptor-interactingdomain,andSRC-
1 interaction domain [108]. The C-terminal glutamine-rich
domain of CBP/p300 forms contacts with other coacti-
vators, most notably those involved in nuclear hormone-
receptor signaling pathways. The complexity and breadth
of CBP/p300 interactions attest to the unique involvement
of CBP/p300 in the transcriptional control as universal and
versatile cointegrators.
CBP and p300 directly interact with the ligand-binding
domain of several nuclear receptors including PPARs [110].
C-terminal of PPARα that corresponds to AF-2 domain
(residues 448–468) is required for the interaction with N-
terminal region of p300 spanning aa 39–117, and also the
N-terminal fragment of CBP encompassing aa 1–115 in
a ligand dependent manner. Fragments of both p300 and
CBP that interact with PPARα contain one LXXLL motif
[110]. Interaction of CBP and p300 with the ligand-binding
domain of PPARα or PPARβ was demonstrated in human
intestine-like Caco2 cell line [111]. Induction of confor-
mational change and transactivation potential of PPARβPPAR Research 7
was considerably lower than that of PPARα in response
to arachidonic acid, as well as other polyunsaturated fatty
acids [112]. Arachidonic acid enhanced binding of p300 to
PPARα but not to PPARβ. Additionally, arachidonic acid
induced in vitro binding of both PPARα-RXRα and PPARβ-
RXRα heterodimers to several PPREs [113, 114]. CBP, which
is highly expressed in brown fat, also coactivates PPARα-
dependent regulation of the UCP-1 gene promoter in the
HepG2 cells in the presence of PPARα ligand, Wy-14,643
[115]. Presence of CBP in PRIC complex that interacts
with full-length PPARα in the presence of ciproﬁbrate and
leukotrieneB4alsosubstantiatethecoactivatorstatusofCBP
[63].
p300 interacts with the N- and C-terminal regions of
PPARγ in a ligand-independent and -dependent manner,
respectively [116]. Leu-311, Asn-312, and Thr-316 in helix
4o fP P A R γ ligand-binding domain are involved in PPARγ
binding with CBP [117]. Deletion of A/B-domain of PPARγ
compromises recruitment or stabilization of CBP- and p300-
containing cofactor complexes on a subset of target genes
involved in lipid storage [118]. Both PPARγ and CBP are
e x p r e s s e di np r e a d i p o c y t e sa n dd i ﬀerentiated adipocytes
suggesting that CBP serves as a physiologically relevant
coactivator for PPARγ signal transduction [119]. p300 also
transactivates PPARγ in the presence of natural ligand 15-
deoxy-Δ12, 14-prostaglandin J2, buttroglitazone, asynthetic
PPARγ ligand, failed to induce PPARγ interactions with
p300. CBP/p300 also increases the transcriptional activity
of PPARγ through PGC-1 which stimulates an apparent
conformational change in PGC-1 that permits binding of
SRC-1 and CBP/p300 resulting transactivation of target
genes [91]. Recruitment of CBP/p300 and PGC-1α was
shown recently on PPARγ/RXRα heterodimer bound to the
promoter of UCP-1 gene after the activation of β-adrenergic
receptorinJhdm2aknockoutmice[120].Jhdm2aisaH3K9-
speciﬁc demethylase that directly regulates PPARα and Ucp1
expression [120]. PPARγ recruits CBP to the aP2 gene pro-
moter as evidence by chromatin immunoprecipitation and
in vitro immunoprecipitation assay in the MEFs induced for
adipogenic diﬀerentiation [121]. Recently, it has been shown
that beraprost, a synthetic analogue of prostacyclin serves as
a ligand for PPARβ that enhances transcriptional activation
of p21/p27 by increasing CBP nuclear translocation, which
contributes to the vasoprotective action in rat aortic smooth
muscle cells [122].
6. PBP (PPARBP)/TRAP220/DRIP205/MED1
PPAR-binding protein (PBP/PPARBP) was ﬁrst cloned
through yeast two-hybrid system using Gal4-PPARγ as
bait to screen a mouse liver cDNA library and iden-
tiﬁed as a nuclear receptor coactivator with 2 LXXLL
motifs [58]. Subsequently, PBP was shown as a critical
component of TRAP/DRIP/ARC/Mediator complex [57,
73, 74, 123, 124] and it is variously referred to as PBP
(PPARBP)/TRAP220/DRIP205/Med1 subunit of Mediator
complex [41]. The Mediator complex was ﬁrst discovered
in yeast and was shown to be essential for pol II depen-
dent transcription [41]. The mammalian Mediator complex
consists of ∼31 subunits and PBP/TRAP220/Med1 is the
prominent member of this complex [73, 75]. Med1 binds
to several nuclear receptors such as PPARα,R A R α,T R β1,
RXR, VDR, FXR, ERα and GR via two conserved LXXLL
motifs in a ligand-dependent manner [58, 74, 121, 123–125],
Med1 also interacts with a variety of other transcriptional
factors, including tumor suppressor p53, ﬁve GATA family
members, p300, PGC-1 and C/EBPβ [46, 79, 126–129].
These interactions imply a major role for Med1 in nuclear
receptor mediated cellular proliferation, diﬀerentiation and
homeostatic regulation [76, 130].
Med1 serves as an anchor for the Mediator complex and
facilitates the linkage between HAT containing CBP/p300
andp160/SRCproteincomplexandpolIIbasaltranscription
machinery in regulating transcription [41, 46]. Phospho-
rylation of Med1 by mitogen-activated protein kinase-
extracellularsignal-regulatedkinase(MAPK-ERK)promotes
its association with Mediator [131, 132]. Med1 is widely
expressed in many tissues of adult mice, including brain,
heart, lung, liver, kidney, adipose tissues, and the most
prominent being the testis [76, 133]. Recently, it has been
reportedthatMed1isatargetformiR-205.miR-205interacts
with a speciﬁc target in the 3 - U T Rs e q u e n c eo fM e d 1a n d
silences its expression in human trophoblasts exposed to
hypoxia [134].
Med1 ablation leads to embryonic lethality at midges-
tation, day 11.5 postcoitum (E11.5), which is attributed, in
part, to defects in the development of placental vasculature,
similar to those encountered in PPARγ [78, 135–137].
Embryonic development of the heart, eye, vasculature and
the hematopoietic system is altered in Med1 null mice.
This phenotype is similar to that in mice deﬁcient in
members of GATA, a family of transcription factors that
modulates diﬀerentiation of adipocytes, megakaryocytes and
erythrocytes [79].
As indicated above, Med1 was ﬁrst identiﬁed as a
PPARγ coactivator and it plays an important role in the
PPARγ signaling pathway [58, 78, 136]. Med1 and PPARγ
interaction requires two LXXLL nuclear receptor recognition
motifs present in Med1 [138]. Med1 modestly increases
the transcriptional activity of PPARγ, and a truncated
form of Med1 (aa 487–735) acts as a dominant negative
repressor [74, 123]. It has been shown that the deletion
of 12 amino acids from the extreme carboxyl terminus of
PPARγ results in the abolition of Med1-PPARγ interaction
[58]. However, deletion of the PPARγ A/B-domain does
not aﬀect Med1 recruitment [118]. To study the role of
Med1 in PPARγ-mediated adipogenesis in vitro, Med1+/+
and Med1−/− MEFs were isolated from E10.0 littermate
embryos and infected with a retroviral vector driving PPARγ
[139]. Disruption of TRAP220/Med1 in MEFs is refractory
toPPARγ-stimulatedadipogenesisbutnotMyoD-stimulated
myogenesis [139]. Surprisingly however, a conserved N-
terminalregionofMed1thatlackstheLXXLLmotifsbutgets
incorporatedintoMediatorfullysupportsPPARγ-stimulated
adipogenesis [138]. A direct interaction between PPARγ
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for PPARγ-stimulated adipogenesis and for PPARγ target
gene expression in cultured ﬁbroblasts [138]. Furthermore,
PPARγ target gene expression and recruitment of Mediator
to a PPARγ response element on the aP2 promoter in
undiﬀerentiated MEFs do not require Med1 [138]. These
ﬁndings imply that the presence of alternative mechanisms
for Mediator recruitment, possibly through intermediate
cofactors or other cofactors that are functionally redundant
with Med1 [138].
To further study the role of Med1 in speciﬁc tissues in
vivo, mice carrying ﬂoxed Med1 alleles were generated for
conditional null mutation [140, 141]. Conditional deletion
of Med1 gene in liver results in the abrogation of PPARα
ligand-induced pleiotropic eﬀects, indicating that Med1
is essential for PPARα signaling and fatty acid oxidation
[140]. Med1 deﬁciency in liver parenchymal cells results
in the near abrogation of PPARα ligand-induced peroxi-
some proliferation, liver cell proliferation, and induction
of PPARα-regulated genes. In contrast, scattered residual
Med1+/+ hepatocytes that escape Cre-mediated excision of
ﬂoxed alleles in Med1 liver nulls, show DNA synthesis and
were markedly hypertrophic with peroxisome proliferation
in response to PPARα ligands (Figures 3(a) and 3(b)).
Med1−/− hepatocytes are refractory for PPARα ligand-
inducedperoxisome proliferation [140].Moreover,Med1ΔLiv
mice, chronically exposed to PPARα ligand Wy-14,643, show
a striking proliferative response and clonal expansion of
residual Med1+/+ hepatocytes (Figures 3(c) and 3(d)) but
no proliferative expansion of Med1−/− hepatocytes occurs
andtheseMed1nullhepatocyteappearedhypoplastic(boxed
areas in Figures 3(c)–3(e)) as compared to hyperplastic large
Med1+/+ hepatocytes.
Surprisingly, the Med1 liver conditional null mice
develop liver tumors on long-term exposure to PPARα
ligand, but all tumors developing in Med1ΔLiv mice reveal
Med1 expression and no tumors developed from Med1−/−
hepatocytes [142]. These data suggest that Med1 plays a
key role in PPARα ligand-induced liver tumor development
and that cells deﬁcient in Med1 do not give rise to tumors
[142]. Furthermore, initiation by a genotoxic carcinogen
diethylnitrosamine followed by phenobarbital promotion
in Med1ΔLiv mice results in a failure of Med1 null hep-
atocytes to undergo proliferation. As in the case of Wy-
14,643 treatment, all hepatocellular carcinomas developing
in Med1ΔLiv mice are Med1 positive [143]. Liver tumors
that develop in Med1ΔLiv mouse livers are transplantable in
athymic nude mice and these maintain Med1ﬂ/ﬂ genotype.
TheseobservationsimplythatMed1isessentialforthedevel-
opmentofhepatocellularcarcinomainthemouse[143].The
failure of Med1 null hepatocytes to develop liver tumors
following PPARα ligand administration or after prolonged
promotion with phenobarbital, which is an activator for
nuclear receptor constitutive androstane receptor (CAR),
implies that coactivator Med1 is a critical component of
PPARα and CAR signaling and thus participates in the
neoplastic process [142–144]. Med1 deﬁcient livers fail to
develophepaticsteatosisinducedbyglucorcorticoidreceptor
(GR) agonist [145] and also fail to develop hepatic steatosis
when induced by PPARγ overexpression (unpublished data).
In addition, using a conditional null mutation, it has
been shown that Med1 is required for mammary gland
development [146], and is also essential for the growth of
Notch4-immortalized mammary cells by activating SOX10
expression [147]. Earlier studies have demonstrated the
Med1 is either overexpressed or ampliﬁed in several breast
carcinomas implying that Med1 plays a role in ER signaling
and cancer [125, 148]. More recently, Med1 has been shown
to play an important coregulatory role in prostate cancer
cell proliferation and survival [149]. However, decrease of
Med1 expression in human melanoma cells increases their
tumorigenic phenotype and the reason for this discordancy
is unclear [150].
In summary, using conditional knockout mice, it has
been established that Med1 subunit is essential for the
signaling of nuclear receptors PPARγ,P P A R α, CAR and
GR [139–145]. Evidence indicates that Med1-deﬁciency does
not lead to the disintegration of the Mediator complex as
originally speculated but it is possible that Mediator complex
devoid of Med1 subunit may be impaired in its ability to
recruit pol II to transduce the transcriptional signal [151].
7. PGC-1FamilyinCoactivationof PPAR
PGC-1 family of coactivators, with three members, plays
a critical role in the maintenance of mitochondrial func-
tion, thermogenesis and energy homeostasis [59]. The ﬁrst
member of the PGC-1 family was identiﬁed as a PPARγ-
interacting protein from brown fat cDNA library using
yeast two-hybrid screen and is now termed PGC-1α [59].
Thereafter, two related coactivators, PGC-1β (also termed
PERC) and PGC-1-related coactivator (PRC) were discov-
ered through searches of new data base entries [60, 152].
PGC-1α and PGC-1β share similar tissue distribution with
highest levels of expression in brown fat, heart and slow-
twitch skeletal muscle [59, 152], and their mRNA levels are
induced signiﬁcantly in the adult liver following fasting [152,
153]. Expression of PGC-1α mRNA is also elevated in brown
fat after cold exposure, whereas PGC-1β does not respond
[59, 152]. Less is known about the expression patterns and
biological roles of PRC [60].
In addition to PPARγ,P G C - 1 α also coactivates a variety
of other nuclear receptors, including PPARα [154], PPARβ
[21], TRβ [59], ERα [59], GR [155], FXR [156], LXR [157],
HNF4 [152]a n dR A R ,b u tn o tR X R α [59]. Cotransfection
experiments in cells show that PGC-1α increases the PPARα-
mediated transcriptional activity and that AF2-LXXLL inter-
action is necessary for the coactivation of PPARα by PGC-
1α [154]. Furthermore, overexpression of PPARα and PGC-
1α in 3T3L1 cells cooperatively induces the expression
of mitochondrial fatty acid β-oxidation enzyme system
genes and increases cellular palmitate oxidation rates [154].
PPARα-driven mitochondrial biogenic response reveals that
expression of PGC-1α is activated in wild-type mice but not
in PPARα-deﬁcient mice [158]. PGC-1α promotes expres-
sion of mammaliantribbles homolog TRB-3 through PPARα
and knockdown of hepatic TRB-3 expression improves
glucose tolerance, whereas hepatic overexpression of TRB-3PPAR Research 9
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Figure 3: Eﬀects of Med1 and PRIP deletion on PPARα ligand-induced pleiotropic responses in liver. Med1ΔLiv mice treated with Wy-14,643
(0.125% wt/wt) for 2 weeks (a, b) show an occasional hepatocyte that escaped Alb-Cre mediated deletion of Med1 ﬂoxed alleles. These
Med1 positive hepatocytes respond to the peroxisome proliferative eﬀects of PPARα-ligand (arrows indicate to Med1+/+ cells with numerous
peroxisomes) but not the majority of Med1−/− hepatocytes. Chronic treatment of Med1ΔLiv mice with 0.02% Wy-14,643 for 5 months (c–e)
results in clonal expansion of residual Med1ﬂ/ﬂ cells as demonstrated by H&E staining (c). In contrast, the adjacent hepatocyte lacking Med1
are generally smaller than normal hepatocytes (see boxed area in c). Immunohistochemical localization of Med1 reveals that expanding
colonies of large hepatocytes are Med1 positive (nuclear Med1 in panel d). These cells also show abundant cytoplasmic expression of L-PBE,
thesecondenzymeoftheperoxisomalfattyacidβ-oxidationsystem(panele),whereasthesmallerMed1nullhepatocytes(boxedareas)failt o
show L-PBE induction (panel e). Disruption of coactivator PRIP in hepatocytes does not interfere with PPARα ligand-induced peroxisome
proliferation as evidenced by the abundant catalase positive peroxisomes (brown dots) in all hepatocytes (panel f). Compare this panel (f)
with panel (b) in which only an occasional Med1+/+ cell responds to PPARα ligand.
reversed the insulin-sensitive phenotype of PGC-1-deﬁcient
mice [159].
PGC-1αutilizesadomainrichinprolineresiduestobind
to a region that overlaps the DNA binding and hinge region
ofPPARγ [59].ThestronginteractionofPGC-1αandPPARγ
is mediated through both hydrophobic and speciﬁc polar
interactions. Mutations within the context of the full-length
PGC-1αindicatethattheﬁrstPGC-1αmotifisnecessaryand
suﬃcient for PGC-1α to coactivate PPARγ in the presence
or absence of rosiglitazone [160]. Thiazolidinediones and
rexinoids induce PGC-1α gene expression in brown and
white adipocytes by a PPARγ-dependent pathway. This is
attributed to the presence of a PPARγ-responsive element in
the distal region of the PGC-1α gene promoter that binds
PPARγ/RXR heterodimers [161]. The interaction between
PGC-1αandPPARβdependsontheLXXLLmotifinPGC-1α
(aa142–146)andthisinteractionisenhancedinthepresence
of PPARβ agonist GW501516 [21]. Tetradecylthioacetic acid,
a pan-PPAR ligand, induces hepatic fatty acid oxidation
in PPARα−/− mice possibly through PGC-1α mediated
PPARβ coactivation [162]. Pharmacological activation of
PPARβ induces fatty acid oxidation and this depends upon
PGC-1α as the induction is completely abolished in the
absence of both PGC-1α and PGC-1β [163]. To study10 PPAR Research
the role of PGC-1α in vivo, PGC-1α knockout mice have
been generated [164, 165], which show normal embryonic
development, suggesting that PGC-1α driven coactivation
is not critical for PPARγ and PPARβ functions in the
maintenance of placental adequacy [164, 165]. Interestingly,
PGC-1α−/− mice survive with modestly blunted postnatal
cardiac growth, suggesting that PGC-1α is essential for the
maintenance of maximal, eﬃcient cardiac mitochondrial
fatty acid oxidation, ATP synthesis, and myocardial lipid
homeostasis [165, 166].
Hepatic PGC-1β overexpression results in the attenua-
tionofchangesinducedbyWy-14,643,aPPARαligand[167].
PGC-1β poorly activates the expression of gluconeogenic
genes in hepatocytes or liver in vivo. The reduced ability of
PGC-1β to induce gluconeogenic genes is due, in part, to its
inability to physically associate with and coactivate HNF4α
and FOXO1 [153]. PGC-1β null mice are viable and fertile
and show no overt phenotype. However, PGC-1β deﬁcient
mice display an altered expression in a large number of
nuclear-encoded genes governing mitochondrial functions
in multiple tissues including heart, skeletal muscle, brain,
brown adipose tissue, and liver [168]. PGC-1α null mice
appeared hyperactive in comparison to somewhat sluggish
PGC-1β null mice. When acutely exposed to cold, these
mice develop abnormal hypothermia and morbidity [168].
Furthermore, high-fat feeding induced hepatic steatosis and
increases serum triglyceride and cholesterol levels in the
mutant mice [168].
8. PRIP/NCoA6
Nuclear receptor coactivator PRIP (PPAR-interacting
protein) [168], also referred to as activating signal
cointegrator-2(ASC-2) [83]/nuclear receptor activating
protein 250 (RAP250) [61] / n u c l e a rr e c e p t o rc o r e g u l a t o r
(NRC)[84]/thyroidhormonereceptor(TR)-bindingprotein
(TRBP)[85],wascloned bydiﬀerentgroups using yeasttwo-
hybridscreenswithanuclearreceptorasbait.PRIP(NCoA6)
was identiﬁed as a ligand-dependent nuclear receptor-
interacting protein. PRIP forms large steady-state complex
of approximately 2MDa (ASC-2 complex [ASCOM] with
retinoblastoma-binding protein RBQ-3, α/β-tubulins and
subset of Trithorax-related proteins [169]. PRIP, like MED1
gene is also ampliﬁed and overexpressed in breast, colon
and lung cancers [170, 171]. PRIP and PRIP-interacting
protein with methyltransferase domain (PIMT/NCoA6IP)
appears to serve as a linker between CBP/p300-anchored
and Mediator complexes. PRIP contains two LXXLL motifs,
one at the N-terminal region (aa 892 to 896) plays a pivotal
role for ligand-dependent interactions with a wide spectrum
of nuclear receptors including PPARs, TRs, RXRs, ERs, GR,
VDR and RARs [64, 81, 83] and the second LXXLL located
at the C-terminal does not bind with PPARs, RAR, RXRs,
and GR but does bind with LXRα and LXRβ [85, 172–174].
These two LXXLLs interact with LXRs and other nuclear
receptors and regulate insulin secretion and maintain β-cell
function [175].
PRIP acts as a strong coactivator for PPARγ,a n da
truncated form of PRIP (aa 786–1132) acts as a dominant-
negative repressor [62]. It is worth noting that PRIP is also
detected in the transcriptionally active PPARα interacting
cofactor (PRIC) complex isolated from rat liver [63]. PRIP
protein expression has been detected in many tissues,
especially in the reproductive organs such as testis, prostate
and ovary [76, 176]. In the testis and ovary, PRIP immunos-
taining shows intense staining of the nuclei of Sertoli
and follicular granulosa cells respectively [177]. Mice with
disrupted PRIP/RAP250/NRC/AIB3 gene die at embryonic
stage E11.5 and E12.5 days. PRIP mutant embryo mortality
has been attributed to placental dysfunction including
the failure of labyrinthine development, the dilation of
maternal blood sinuses, the massive erythrophagocytosis by
trophoblastic cells, alteration in trophoblast population and
the formation of fewer blood vessels in extra-embryonic
membrane covering the embryo [76, 85, 170, 173, 178, 179].
In addition, developmental abnormalities in heart, liver,
and the nervous system have been noted [85, 173, 178].
Interestingly, MEFs derived from PRIP/NRC null embryos
display growth retardation and apoptosis [176]. Further
studieswithheterozygousPRIP/NRC+/− showaspontaneous
wound healing deﬁciency, suggesting that PRIP/NRC is
important in maintaining integrity during wound heal-
ing [176, 180]. Haploid inactivation of PRIP/AIB3 in
AIB3+/−/PyMT bitransgenic mice cause inhibition of cell
proliferation mediated by PPARγ/RXR [181].
PRIP null MEFs are also resistant to PPARγ stimulated
adipogenesis [121]. This defect occurs because of apparent
disruption of the linkage between the CBP/p300 anchored
subunit complex and the MED1-dependent mediator com-
plex [121]. In order to investigate the physiological role
of PRIP in vivo, conditional knockout mice have been
generated [182]. Conditional PRIP null mutation in the
mouse mammary gland results in defective mammopoiesis,
similar to that encountered in Med1 deﬁcient mammary
glands [146, 168]. To further understand the function of
PRIP in mammary gland tumorigenesis, a mammary tumor
cell line with the PRIPloxP/loxP genotype was established and
disruption of the PRIP gene in these cells has been shown
to abrogate their tumorigenic potential. PRIP deﬁciency
substantially reduced the expression of FOS gene [171].
Liver-speciﬁc disruption of the PRIP gene fails to aﬀect
the induction of PPARα-regulated pleiotropic responses,
including hepatomegaly, hepatic peroxisome proliferation
(Figure 3(f)), and induction of genes involved in the fatty
acid oxidation systems [182]. These results are dissimilar to
those encountered with liver speciﬁc MED1 gene disruption
[140], indicating that PRIP is not essential for PPARα target
gene activation in liver [182].
9.PRIC285
PRIC complex isolated from the rat liver nuclear extract
using full-length GST-PPARα fusion protein in the presence
of a PPARα ligand comprises of ∼25 subunits [63]. A
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PPARα ligand (ciproﬁbrate)-aﬃnity matrix [64]. MALDI-
TOF analysis of the components of PRIC complex showed
identities of many already known genes identiﬁed in yeast
two-hybrid screens known to be involved in transcriptional
regulation and some novel proteins [63]. This complex
includes CBP/p300, p160/SRC-1, MED1, PRIP, PIMT and
novel coactivators designated as PRIC285, PRIC295, and
PRIC320 based on estimated molecular size (see [63, 64],
unpublished data). PRIC285 is a component in the PRIC
complex isolated using ciproﬁbrate or LTB4 as ligand in
GST PPARα pull down system [63]. Subsequently, a longer
isoform has been cloned using human PPARγ as bait in yeast
two-hybrid screen and has been referred to as PPARγ-DBD-
interacting protein 1 (PDIP1)-α [183]. PRIC285 is expressed
in multiple human tissues such as skeletal muscle, colon,
spleen, liver, kidney, heart, lung, pancreas, small intestine,
thymus, prostate, ovary, peripheral blood, and placenta
[63] .P R I C 2 8 5h a sb e e nd e t e c t e di ns e v e r a lh u m a nc a n c e r
lines such as HeLa, colorectal adenocarcinoma SW480,
melanoma, HepG2, medulloblastoma HTB185, and DU145
(prostate) [63, 183].
The human PRIC285 gene, which spans ∼16.1kb, is
located on chromosome 20 at position 20q13.33 and it
encodes a protein of 2080 amino acid with an estimated
molecular mass of 285kDa [63]. PRIC285 contains ﬁve
LXXLL signature motifs at aa 506–510; 549–553; 604–608;
1443–1447; 1660–1664 [183]. It appears that none of these
LXXLL motifs of PRIC285 is needed for interaction with
PPARs as demonstrated by mutating LXXLL motifs [183].
PRIC285 binds to the DBD-hinge (DBD-H) of the PPARs
through its C-terminal region mapped at aa 1675–1823
[183]. Comparison of the amino acid sequences ﬂanking
core LXXLL motifs in PRIC285 with those identiﬁed in other
coactivators revealed that this conﬁguration did not ﬁt well
with the proposed alignment rules [184]. Other than LXXLL
signature motifs human PRIC285 also displays amino acid
sequence homologous to RnaseB (RNB) and UvrD/REP
motifs, a superfamily I DNA helicase [63, 183]. It is found
to be transcriptional coactivator for the PPARα,P P A R δ/β
and PPARγ in transfected cells. Cotransfection of PPARα
and PRIC285 into HEK293 cells stimulates transcription
of PPRE-TK-Luc gene in the presence of ciproﬁbrate, a
PPARα speciﬁc ligand. This interaction between PRIC285
and PPARα was also shown by the colocalization in nucleus
of 293 cells [63]. Transactivation of PPARα by PRIC285 also
occurs after treatment with a diﬀerent PPARα ligand, fenoﬁ-
brate [183]. Human PRIC285 has been shown to enhance
PPARγ-mediated transactivation of DR1 reporter gene using
the synthetic PPARγ ligand troglitazone. PRIC285 also
coactivates PPARβ in the transactivation assay where CV-
1 cells were treated with PPARβ ligand cyclic prostaglandin
[183].
To assess the biological signiﬁcance of PRIC285, we
have generated whole-body gene knockout mice using
two-loxP and two-frt system and characterized them for
PPARα-mediated transcriptional activation in vivo [185].
Mice homozygous for PRIC285 mutation (PRIC285−/−)a r e
apparently healthy and fertile and show no consistent phe-
notypic diﬀerences when compared to their wild-type ﬂoxed
littermates (PRIC285ﬂ/ﬂ). When challenged with PPARα
ligands, such as Wy-14,643 or ciproﬁbrate, no diﬀerences
were observed in the magnitude of pleiotropic responses,
which include hepatomegaly, peroxisome proliferation in
hepatocytes, and increased levels of PPARα target genes
suchasperoxisomalandmitochondrialβ-oxidationenzymes
[185]. The role of PRIC285 in PPARγ mediated adipogenesis
in the liver has been examined using PRIC285 null mice.
Adenovirally driven PPARγ gene when injected through tail
vein induced hepatic steatosis in both PRIC285 null and wild
type ﬂoxed littermates to delineate the role of the coactivator
PRIC285 in hepatic steatosis. No discernible diﬀerences in
the PPARγ-mediated hepatic adipogenic steatosis in the
normal and mutant PRIC285 mouse liver has been noted
[L. Bai, unpublished]. These results may point to a func-
tional redundancy of PRIC285 in the general transcriptional
machinery as far as PPARα and PPARγ are concerned. The
discordance between in vitro and in vivo results of PRIC285
function reﬂects the complexity and redundancy in that loss
of a single component of a multisubunit protein complex
could be compensated in vivo by other members of this
mega complex. Nonetheless, it would be a challenge for
the immediate future to assess the role of PRIC285 in the
signaling of other nuclear receptors in vivo using the whole-
body or conditional deletion.
10. PRIC320/CReMM/CHD9: ATP Dependent
Chromatin Remodeling Activity
PRIC320 was identiﬁed in high molecular weight protein
complex isolated using ciproﬁbrate coupled AH-sepharose
aﬃnity pulldown from the rat liver nuclear extract [64].
PRIC320 is also known as chromodomain helicase DNA
binding protein 9 (CHD9)/Chromatin Related Mesenchy-
mal Modulator (CReMM). It is a member of the CHD
(chromodomain-helicase-DNA-binding) family of proteins
that interacts with nucleosomes and plays a role in chro-
matin remodeling to modulate transcription [64, 186–188].
Members of the CHD family of enzymes belong to the
SWI/SNF2 (SWItch/Sucrose Nonfermentable) superfamily
of ATP-dependent chromatin remodelers. PRIC320 dis-
plays two tandem N-terminal chromodomains (aa 692–
752; 774–826) that function as interaction surfaces for a
variety of chromatin components. It also contains SNF2-like
ATPase/DEAD-like helicase domain (aa 879–1028) located
in the central region of the protein structure [189, 190]. A
C-terminal cluster of domains such as paired BRK (Brahma
and Kismet; aa 2483–2532; 2557–2601) domains, a SANT-
like domain, and a DNA-binding domain are also present
in PRIC320 [64, 191, 192]. The SNF2-like ATPase/DEAD-
like helicase domain contains a conserved set of amino acid
motifs that has been found in proteins involved in many of
cellular processes including chromatin assembly, transcrip-
tion regulation, DNA repair, DNA replication, development
and diﬀerentiation [69, 193]. PRIC320 contains ﬁve LXXLL
signature motifs that mediate interaction with nuclear
receptors [64].12 PPAR Research
Two isoforms of PRIC320 designated as PRIC320-1 and
PRIC320-2 that encode aa 2882 and 1995, respectively,
have been identiﬁed in the human [64]. PRIC320-1 with
an estimated molecular weight of 320kDa contains all ﬁve
LXXLL motifs located at aa 868–872; 1036–1040; 2031–
2035; 2706–2710; and 2778–2782, whereas PRIC320-2 with
an estimated molecular weight of 240kDa contains distal
four LXXLL motifs. The gene encoding human PRIC320 is
mapped to long arm of chromosome at 16q12.2 (Ensembl;
www.ensembl.org). PRIC320 transcript is present in various
human tissues though at very low levels. PRIC320 mRNA
has been detected in cancer cell lines such as HL-60,
HeLa, Burkitt’s lymphoma Raji and colorectal and lung
carcinoma [64]. Cancer cell lines such as HL-60, HeLa cells,
are shown to express two isoforms of mRNA 11.5kb and
10.5kb corresponding to PRIC320-1 and PRIC320-2. In
mice, expression of PRIC320 is higher in brain, followed by
heart, kidney, and skeletal muscle [64].
PRIC320 interacts with PPARα and functions as a
coactivator in vitro [64]. Full length PPARα fused to GST
interacts with both PRIC320 isoforms in a ligand dependent
manner whereas interaction with PPARγ appeared minimal
[64]. This selectivity for PPARs indicates a diﬀerential role of
PRIC320 in the regulation of downstream target genes. The
recognition in PRIC320/CHD9 of chromatin remodeling
function and nuclear receptor coactivator function is sug-
gestive of the multiple roles played by these nuclear receptor
cofactors.
11. SWI/SNF: ATP-Dependent Chromatin
Remodeling Complex
The SWI/SNF (mating type switch/Sucrose Nonfermenting)
families of chromatin remodeling complexes mobilize nucle-
osomes and function as master regulators of transcription
factor function. Although the precise mechanisms by which
SWI/SNFmodiﬁes chromatin structureremains unclear,this
process involves a conformational change of nucleosome
and chromatin-remodeling in an ATP-dependent manner
[65, 66]. SWI/SNF complex contains one or two possible
ATPases, BRM (Brahma) or BRG1 (Brahma-Related gene
1) [194]. Chromatin remodelling represents an important
step in adipocyte diﬀerentiation. C/EBPα, which is known
to interact with the pol II-associated general transcription
factors TBP/TFIIB, also interacts with BRM of the human
SWI/SNF complex [195]. PPARγ depends on a speciﬁc
BRG1-containingSWI/SNFcomplextoactivateadipogenesis
under in vitro conditions [196]. SWI/SNF complex and
TFIIH are recruited on the promoter of PPARγ to trans-
activate PPARγ [197]. The docking of SWI/SNF complex
on PPARγ promoter occurs through the subunit BAF60c
(BRG1/Brm-associated factor subunit c) [69]. Recently, an
interaction between SWI/SNF complexes and PPARα was
demonstrated through BAF60a. SWI/SNF also plays a role in
the regulation of the hepatic lipid metabolism through the
fatty acid oxidation [67].
12. BAF(s) Family
The BAF (BRG1/Brm-associated factor) family represents
the accessory subunits of SWI/SNF complexes that act as
the connection between transcription factors and SWI/SNF
complexes. Several BAFs been identiﬁed which include
BAF250,BAF170,BAF155,BAF60,BAF57andBAF53a[198–
200]. Recent studies have implicated the BAF60 family mem-
bers, including BAF60a, BAF60b and BAF60c, in mediating
the interaction between the SWI/SNF complexes and target
transcription factors. BAF60a or SMARCD1 (SWI/SNF
related, matrix associated, actin-dependent regulator of
chromatin subfamily d, member 1), a protein of 60kDa, is
known to be the connection between SWI/SNF and GR [68].
More recently, BAF60a was identiﬁed as a molecular link
between SWI/SNF complexes and hepatic lipid metabolism.
Adenoviral expression of BAF60a has been shown to stim-
ulate fatty acid β-oxidation in primary hepatocytes culture
to ameliorate hepatic steatosis in vivo. PGC-1α mediates
the recruitment of BAF60a to the PPRE and enhances the
transcription of PPARα regulated fatty acid oxidation system
genes [67]. BAF60a is considered as a regulator of hepatic
lipid metabolism. BAF60c or SMARCD3 (SWI/SNF related,
matrix associated, actin dependent regulator of chromatin
subfamilyd,member3),whichisalsoa60kDaprotein,binds
to several nuclear receptors, including PPARγ,E R α,a n d
RORα [69]. Recently, a new regulator of PPARγ, the subunit
BAF60c2 has been identiﬁed in a yeast two-hybrid screen of
a human adipose tissue cDNA library. BAF60c2 represents
a new isoform of BAF60c, which allows the recruitment of
SWI/SNF to the nuclear receptor. Two isoforms BAF60c1
and BAF60c2 are localized primarily in the nucleus and
are expressed in a wide variety of tissues. BAF60c proteins
interact in a ligand-independent manner with PPARγ and
enhance its transcriptional activity [69].
13. PIMT
PIMT (NCoA6IP, TGS1) was ﬁrst isolated as a PRIP
(NCoA6)-interacting protein [70]. PIMT is an RNA methyl-
transferase and was cloned from a human liver cDNA library
using PRIP as bait in yeast two-hybrid assay. Human PIMT
protein contains 852 amino acids. It has a methyltransferase
motif at the C- terminus and an RNA-binding domain at the
N-terminus [70]. PIMT is an evolutionarily conserved pro-
teinfoundinC.elegans,Arabidopsisthaliana,andyeast[70].
PIMT serves as a linker between multiprotein complexes
anchored by CBP/p300 and PBP/MED1. PIMT enhances
Med1mediated transcriptional activity of the PPARγ which
was increased by PRIP [70, 79, 201]. Consistent with its
RNA methyltransferase function, PIMT homologue in yeast
known as trimethylguanosine synthase1 (TGS1), plays a
role in the formation of the 2, 2, 7-trimethylguanosine
(m3G) 5 -cap structure of snRNAs and small snoRNAs
[202]. In Drosophila it is designated as DTL (Drosophila
Tat-like) where it is important in development [203]. PIMT
is localized predominantly to the nucleus. It is expressed in
most adult tissues and in all embryonic stages in the mousePPAR Research 13
[76]. Inhibition of PIMT by siRNA in HeLa cells results in
G2/M phase arrest [204].
In order to investigate the biological functions of this
gene in mammalian development and growth, PIMT gene
knockout mice have been generated [205]. Heterozygous
(PIMT+/−) mice grow normally and are indistinguishable
from their wild-type (PIMT+/+) littermates. Disruption of
both PIMT alleles results in early embryonic lethality due
to apoptosis and decreased proliferative potential of the
blastocyst cells [205]. PIMT deﬁcient embryos die shortly
after implantation and then resorbed. PIMTﬂ/ﬂ MEFs treated
with adenovirus expressing Cre showed defective wound
healingandG2phasearrestofcellcycle.Theseresultssuggest
that PIMT is important for early embryonic development of
mice [205].
14. CARM1
Protein methylation is involved in regulating protein-
protein interactions that aﬀect key cellular events, includ-
ing regulation of transcription [206]. Proteins can be
methylated irreversibly on the side-chain nitrogens of the
amino acids arginine, lysine, and histidine in a reaction
with S-adenosylmethionine (AdoMet) [207]. Coactivator-
associated arginine methyltransferase (CARM1)/protein
arginine Nmethyltransferase 4 (PRMT4) is identiﬁed as a
binding partner of SRC-2/GRIP1 (glucocorticoid receptor-
interacting protein 1) [71]. Recently, CARM1 shown to
promote adipocyte diﬀerentiation by coactivating PPARγ
using cDNA microarray and serial analysis of gene expres-
sion (SAGE) [208]. CARM1 also stimulates transcriptional
activation by nuclear receptors in combination with the
p160 family of coactivators [71]. The p160/SRC coactivators
recruit CBP/p300 and CARM1 via two activation domains,
AD1 and AD2 [71]. AD1 binds CBP or p300, whereas
AD2 has been shown to activate transcription through the
recruitment of the arginine methyltransferase CARM1. The
ternary complex of p160-CARM1-CBP/p300 functions syn-
ergistically to enhance transcriptional activation by nuclear
receptors. CARM1 eﬃciently methylates three arginine
residues (R714, R742 and R768) spanning aa 685–774 of
CBP which are also conserved in p300 to transactivate SRC-
2/GRIP-1 [209]. Other than these three methylated arginine
residues, CARM1 also methylates KIX domain of CBP/p300
to block the interaction with KID domain of CREB (Cyclic
AMP response element binding protein) [210]. Methylation
is an irreversible process but peptidyl deiminase 4 removes
methylated arginine from the p300 (Arg-2142) which is
localized in the p160-binding domain to inhibit the bimolec-
ular interactions between p300 and GRIP1. The functional
signiﬁcance of the methylation and demethylimination of
the arginine residue of p300 may be a key mechanism in
p300/CBP-p160-CARM1coactivatorsynergy.Methylationof
p300/CBP by CARM1 promotes a conformational change
that allows the p300-p160 interaction in the complex and
facilitatesadditionalstepsintranscriptionalactivation[211].
Although CARM1 methylates CBP/p300 to enhance
protein-protein interaction in the activated nuclear receptor
complex, it also methylates histone tail, preferentially H3
which in turn relaxes chromatin to generate a docking site
for coactivators and other transcriptional factors on the
promoter of the target genes [71, 212, 213]. Methylation
of the Q-rich domain of SRC-3 through CARM1 has an
antagonizing activity on ER-mediated transcriptional activa-
tion [214]. During estrogen signaling methylation of SRC-
3/AIB1 by CARM1 attenuates the transcriptional response
bydissociatingSRC-3/CARM1coactivatorcomplexfromthe
ER receptor and thus completing a dynamic equilibrium of
receptor-mediated coactivator assembly and disassembly at
the promoter [214]. Mice deﬁcient in CARM1 die at the
perinatal stage emphasizing that CARM1 is crucial during
late embryonic development or immediately after birth
[215]. Methylation of CBP/p300 was shown to be abolished
in the CARM1 knockout embryos and cells. Thus, it appears
that CARM1 mediated methylation is needed for interaction
between p/160 family of proteins and CBP/p300 to maintain
general transcript integrity.
15. Coactivator Activator (CoAA) with
RNA SplicingActivity
The Coactivator activator (CoAA) was ﬁrst identiﬁed as
a protein associated with PRIP/TRBP (thyroid hormone
receptor-binding protein) in a yeast two-hybrid screen [72].
CoAA functions as a general activator of transcription
for several nuclear receptors and stimulates transcription
through its interaction with the C-terminal of PRIP/TRBP
[72]. CoAA interacts with both PRIP/TRBP and p300 in
vitro. The PRIP-interaction domain on CoAA protein is
localized at the central region, which is encoded by exon
2o fC o A Ag e n e[ 72]. In addition, CoAA potently coacti-
vates transcription mediated by multiple hormone-response
elements and acts synergistically with PRIP/TRBP and CBP.
Thus, CoAA appears to function as a coactivator associated
protein. Apart from participating in PRIP/TRBPmediated
transcription, CoAA also regulates alternative splicing in a
promoter-dependent manner [72]. The N-terminal region
of the CoAA protein contains two RNA recognition motifs
(RRMs) at amino acid position 3–68 and 81–144. Both
RRMs are composed of two conserved ribonucleoprotein
(RNP) consensus motifs that regulate posttranslational RNA
splicing [216]. Coactivator modulator (CoAM), a splice
variant is generated as a result of alternative splicing of
exon 2 of the CoAA. CoAM, which lacks a PRIP/TRBP-
interacting domain, represses both PRIP/TRBP and CBP
action suggesting that CoAM may modulate endogenous
CoAA function [72]. In conclusion, CoAA and PIMT, both
capable of interacting with PRIP/TRBP/NCoA6 appear to
function as regulators of RNA processing.
16. Conclusion
During the past 15 years, using yeast 2 hybrid screening
[51, 52, 58, 59, 84], aﬃnity pulldown of nuclear extracts via
covalently bound ligand to the sepharose matrix [63], GST-
receptor pulldown [64] and proteomic approaches [217],14 PPAR Research
over 300 nuclear receptor transciption cofactors have been
identiﬁed. Transcriptional control is a multistep process, a
fact reﬂected in the diversity of the coregulators, and their
intrinsic enzyme activities. These coregulators are possibly
organized into stable, preformed multiprotein complexes,
the modular character of which may facilitate the eﬃcient
assembly of functionally diverse complexes by a liganded
nuclear receptor. In addition, the modular character of these
complexes provides the potential for diﬀerent activators to
assemble diverse conﬁgurations of regulatory complexes at
their cognate cis-acting elements. Emerging genomic and
proteomic approaches promise to advance the characteriza-
tionofcoactivatorproteinsandtheirphysiologicalfunctions.
It should be worth noting that of the many cofactors, about
165 coactivators have been implicated to date in various
human diseases [218]. Gene knockout mouse models have
clearly established that Med1 is necessary for PPARα and
PPARγ functions and that SRC-1, SRC-2, and SRC-3 are
redundant for PPARα function. It is anticipated that further
studies of nuclear receptor coregulators and their complexes
will yield signiﬁcant insights into the basis of the complexity
of signaling by PPARs and their ligands.
Acknowledgment
ThispaperwassupportedbyNIHGrantno.DK083163(J.K.
Reddy).
References
[1] J. K. Reddy and T. P. Krishnakantha, “Hepatic peroxisome
proliferation: induction by two novel compounds struc-
turallyunrelatedtocloﬁbrate,”Science,vol.190,no.4216,pp.
787–789, 1975.
[2] J. K. Reddy, M. S. Rao, and D. E. Moody, “Hepatocellular
carcinomas in acatalasemic mice treated with Nafenopin,
a hypolipidemic peroxisome proliferator,” Cancer Research,
vol. 36, no. 4, pp. 1211–1217, 1976.
[ 3 ]J .K .R e d d y ,D .L .A z a r n o ﬀ, and C. E. Hignite, “Hypolipi-
daemic hepatic peroxisome proliferators form a novel class
ofchemicalcarcinogens,” Nature,vol.283,no.5745,pp.397–
398, 1980.
[ 4 ]J .K .R e d d y ,S .K .G o e l ,a n dM .R .N e m a l i ,“ T r a n s c r i p t i o n a l
regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-
CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat
liver by peroxisome proliferators,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 83,
no. 6, pp. 1747–1751, 1986.
[ 5 ]I .I s s e m a n na n dS .G r e e n ,“ A c t i v a t i o no fam e m b e ro f
the steroid hormone receptor superfamily by peroxisome
proliferators,” Nature, vol. 347, no. 6294, pp. 645–650, 1990.
[6] C. Dreyer, G. Krey, H. Keller, F. Givel, G. Helftenbein, and W.
Wahli, “Control of the peroxisomal β-oxidation pathway by a
novel family of nuclear hormone receptors,” Cell, vol. 68, no.
5, pp. 879–887, 1992.
[7] B. Desvergne and W. Wahli, “Peroxisome proliferator-
activated receptors: nuclear control of metabolism,”
Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[8] L.Michalik,J.Auwerx,J.P.Bergeretal.,“Internationalunion
of pharmacology. LXI. Peroxisome proliferator-activated
receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–
741, 2006.
[ 9 ]A .L .B o o k o u t ,Y .J e o n g ,M .D o w n e s ,R .T .Y u ,R .M .E v a n s ,
and D. J. Mangelsdorf, “Anatomical proﬁling of nuclear
receptor expression reveals a hierarchical transcriptional
network,” Cell, vol. 126, no. 4, pp. 789–799, 2006.
[10] Y. Zhu, C. Qi, J. R. Korenberg et al., “Structural organi-
zation of mouse peroxisome proliferator-activated receptor
γ (mPPARγ) gene: alternative promoter use and diﬀerent
splicing yield two mPPARγ isoforms,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 92, no. 17, pp. 7921–7925, 1995.
[11] M. A. Lazar, “Becoming fat,” Genes and Development, vol. 16,
no. 1, pp. 1–5, 2002.
[12] G. Krey, O. Braissant, F. L’Horset et al., “Fatty acids,
eicosanoids,andhypolipidemicagentsidentiﬁedasligandsof
peroxisome proliferator-activated receptors by coactivator-
dependent receptor ligand assay,” Molecular Endocrinology,
vol. 11, no. 6, pp. 779–791, 1997.
[13] A. Chawla, J. J. Repa, R. M. Evans, and D. J. Mangelsdorf,
“Nuclear receptors and lipid physiology: opening the x-ﬁles,”
Science, vol. 294, no. 5548, pp. 1866–1870, 2001.
[14] T. Hashimoto, W. S. Cook, C. Qi, A. V. Yeldandi, J. K. Reddy,
and M. S. Rao, “Defect in peroxisome proliferator-activated
receptor α-inducible fatty acid oxidation determines the
severity of hepatic steatosis in response to fasting,” The
Journal of Biological Chemistry, vol. 275, no. 37, pp. 28918–
28928, 2000.
[15] S. S.-T. Lee, T. Pineau, J. Drago et al., “Targeted disruption of
theαisoformoftheperoxisomeproliferator-activatedrecep-
tor gene in mice results in abolishment of the pleiotropic
eﬀects of peroxisome proliferators,” Molecular and Cellular
Biology, vol. 15, no. 6, pp. 3012–3022, 1995.
[16] R. Mukherjee, K. T. Locke, B. Miao et al., “Novel peroxisome
proliferator-activated receptor α agonists lower low-density
lipoprotein and triglycerides, raise high-density lipoprotein,
and synergistically increase cholesterol excretion with a liver
Xr e c e p t o ra g o n i s t , ”Journal of Pharmacology and Experimen-
tal Therapeutics, vol. 327, no. 3, pp. 716–726, 2008.
[ 1 7 ] C . - L .M e i ,P .H e ,B .C h e n g ,W .L i u ,Y . - F .W a n g ,a n dJ . - J .W a n ,
“Chlamydia pneumoniae induces macrophage-derived foam
cellformationviaPPARαandPPARγ-dependentpathways,”
Cell Biology International, vol. 33, no. 3, pp. 301–308, 2009.
[18] C. Crisafulli and S. Cuzzocrea, “The role of endogenous and
exogenous ligands for the peroxisome proliferator-activated
receptor alpha (PPAR-α) in the regulation of inﬂammation
in macrophages,” Shock, vol. 32, no. 1, pp. 62–73, 2009.
[19] S. R. Pyper, N. Viswakarma, S. Yu, and J. K. Reddy, “PPARal-
pha: energy combustion, hypolipidemia, inﬂammation and
cancer,” Nuclear Receptor Signalling, vol. 16, no. 8, article
e002, 2010.
[20] J .M.P et ers,S.S.T .L ee,W .Lietal.,“ G r o wths,adipose,brain,
and skin alterations resulting from targeted disruption of
the mouse peroxisome proliferator-activated receptor β(δ),”
MolecularandCellularBiology,vol.20,no.14,pp.5119–5128,
2000.
[21] Y.-X. Wang, C.-H. Lee, S. Tiep et al., “Peroxisome-
proliferator-activated receptor δ activates fat metabolism to
prevent obesity,” Cell, vol. 113, no. 2, pp. 159–170, 2003.
[22] L. M. Sanderson, T. Degenhardt, A. Koppen et al., “Peroxi-
some proliferator-activated receptor β/δ (PPARβ/δ) but not
PPARα serves as a plasma free fatty acid sensor in liver,”
MolecularandCellularBiology,vol.29,no.23,pp.6257–6267,
2009.PPAR Research 15
[23] E. D. Rosen and B. M. Spiegelman, “PPARγ: a nuclear
regulator of metabolism, diﬀerentiation, and cell growth,”
The Journal of Biological Chemistry, vol. 276, no. 41, pp.
37731–37734, 2001.
[24] T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by
which both heterozygous peroxisome proliferator-activated
receptor γ (PPARγ) deﬁciency and PPARγ agonist improve
insulin resistance,” The Journal of Biological Chemistry, vol.
276, no. 44, pp. 41245–41254, 2001.
[25] P. Tontonoz, E. Hu, and B. M. Spiegelman, “Stimulation
of adipogenesis in ﬁbroblasts by PPARγ2, a lipid-activated
transcriptionfactor,”Cell,vol.79,no.7,pp.1147–1156,1994.
[26] S. A. Kliewer, H. E. Xu, M. H. Lambert, and T. M. Willson,
“Peroxisome proliferator-activated receptors: from genes to
physiology,” Recent Progress in Hormone Research, vol. 56, pp.
239–263, 2001.
[27] T. Yamauchi, J. Kamon, H. Waki et al., “The mechanisms by
which both heterozygous peroxisome proliferator-activated
receptor γ (PPARγ) deﬁciency and PPARγ agonist improve
insulin resistance,” The Journal of Biological Chemistry, vol.
276, no. 44, pp. 41245–41254, 2001.
[28] U. Varanasi, R. Chu, Q. Huang, R. Castellon, A. V. Yeldandi,
and J. K. Reddy, “Identiﬁcation of a peroxisome proliferator-
responsiveelementupstreamofthehumanperoxisomalfatty
acyl coenzyme A oxidase gene,” The Journal of Biological
Chemistry, vol. 271, no. 4, pp. 2147–2155, 1996.
[29] J. Direnzo, M. S¨ oderstr¨ om, R. Kurokawa et al., “Peroxisome
proliferator-activated receptors and retinoic acid receptors
diﬀerentially control the interactions of retinoid X receptor
heterodimers with ligands, coactivators, and corepressors,”
Molecular and Cellular Biology, vol. 17, no. 4, pp. 2166–2176,
1997.
[30] V. Chandra, P. Huang, Y. Hamuro et al., “Structure of the
intact PPAR-γ-RXR-α nuclear receptor complex on DNA,”
Nature, vol. 456, no. 7220, pp. 350–356, 2008.
[31] P. Karagianni and J. Wong, “HDAC3: taking the SMRT-N-
CoRrect road to repression,” Oncogene, vol. 26, no. 37, pp.
5439–5449, 2007.
[32] L. Nagy, H.-Y. Kao, D. Chakravarti et al., “Nuclear recep-
tor repression mediated by a complex containing SMRT,
mSin3A, and histone deacetylase,” Cell,v o l .8 9 ,n o .3 ,p p .
373–380, 1997.
[33] L.-N. Wei, X. Hu, D. Chandra, E. Seto, and M. Farooqui,
“Receptor-interacting protein 140 directly recruits histone
deacetylases for gene silencing,” The Journal of Biological
Chemistry, vol. 275, no. 52, pp. 40782–40787, 2000.
[ 3 4 ]K .S .M i y a t a ,S .E .M c C a w ,L .M .M e e r t e n s ,H .V .P a t e l ,
R. A. Rachubinski, and J. P. Capone, “Receptor-interacting
protein 140 interacts with and inhibits transactivation by,
peroxisome proliferator-activated receptor α and liver- X-
receptor α,” Molecular and Cellular Endocrinology, vol. 146,
no. 1-2, pp. 69–76, 1998.
[35] D. Debevec, M. Christian, D. Morganstein et al., “Receptor
interacting protein 140 regulates expression of uncoupling
protein 1 in adipocytes through speciﬁc peroxisome pro-
liferator activated receptor isoforms and estrogen-related
receptor α,” MolecularEndocrinology,vol.21,no.7,pp.1581–
1592, 2007.
[ 3 6 ] Y .K .K a n g,M .G u e rm a h ,C . - X .Y u a n ,a n dR .G .R o e d e r ,“T h e
TRAP/mediator coactivator complex interacts directly with
estrogen receptors α and β through the TRAP220 subunit
and directly enhances estrogen receptor function in vitro,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 99, no. 5, pp. 2642–2647, 2002.
[37] J. W. Conaway, L. Florens, S. Sato et al., “The mammalian
Mediator complex,” FEBS Letters, vol. 579, no. 4, pp. 904–
908, 2005.
[ 3 8 ]P .D o w e l l ,J .E .I s h m a e l ,D .A v r a m ,V .J .P e t e r s o n ,D .J .
Nevrivy, and M. Leid, “Identiﬁcation of nuclear receptor
corepressor as a peroxisome proliferator-activated receptor α
interacting protein,” The Journal of Biological Chemistry, vol.
274, no. 22, pp. 15901–15907, 1999.
[ 3 9 ]H .E .X u ,M .H .L a m b e r t ,V .G .M o n t a n ae ta l . ,“ S t r u c t u r a l
determinants of ligand binding selectivity between the per-
oxisome proliferator-activated receptors,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 98, no. 24, pp. 13919–13924, 2001.
[40] J. D. Chen and R. M. Evans, “A transcriptional co-repressor
that interacts with nuclear hormone receptors,” Nature, vol.
377, no. 6548, pp. 454–457, 1995.
[41] R. D. Kornberg, “The molecular basis of eukaryotic tran-
scription,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 104, no. 32, pp. 12955–
12961, 2007.
[42] M. J. Tetel, A. P. Auger, and T. D. Charlier, “Who’s in charge?
Nuclear receptor coactivator and corepressor function in
brain and behavior,” Frontiers in Neuroendocrinology, vol. 30,
no. 3, pp. 328–342, 2009.
[43] B.W.O’MalleyandR.Kumar,“Nuclearreceptorcoregulators
in cancer biology,” Cancer Research, vol. 69, no. 21, pp. 8217–
8222, 2009.
[44] D. M. Heery, E. Kalkhoven, S. Hoare, and M. G. Parker,
“A signature motif in transcriptional co-activators mediates
binding to nuclear receptors,” Nature, vol. 387, no. 6634, pp.
733–736, 1997.
[45] N. J. McKenna and B. W. O’Malley, “Minireview: nuclear
receptor coactivators—an update,” Endocrinology, vol. 143,
no. 7, pp. 2461–2465, 2002.
[46] R. G. Roeder, “Transcriptional regulation and the role of
diverse coactivators in animal cells,” FEBS Letters, vol. 579,
no. 4, pp. 909–915, 2005.
[47] R. P. S. Kwok, J. R. Lundblad, J. C. Chrivia et al., “Nuclear
protein CBP is a coactivator for the transcription factor
CREB,” Nature, vol. 370, no. 6486, pp. 223–226, 1994.
[48] D. Chekravarti, V. J. LaMorte, M. C. Nelson et al., “Role of
CBP/P300 in nuclear receptor signalling,” Nature, vol. 383,
no. 6595, pp. 99–103, 1996.
[49] R. H. Goodman and S. Smolik, “CBP/p300 in cell growth,
transformation, and development,” Genes and Development,
vol. 14, no. 13, pp. 1553–1577, 2000.
[50] Z. Wang, C. Qi, A. Krones et al., “Critical roles of the
p160 transcriptional coactivators p/CIP and SRC-1 in energy
balance,” Cell Metabolism, vol. 3, no. 2, pp. 111–122, 2006.
[51] S. A. Onate, S. Y. Tsai, M.-J. Tsai, and B. W. O’Malley,
“Sequence and characterization of a coactivator for the
steroid hormone receptor superfamily,” Science, vol. 270, no.
5240, pp. 1354–1357, 1995.
[52] Y. Zhu, C. Qi, C. Calandra, M. S. Rao, and J. K. Reddy,
“Cloning and identiﬁcation of mouse steroid receptor
coactivator-1 (mSRC-1), as a coactivator of peroxisome
proliferator-activated receptor gamma,” Gene Expression, vol.
6, no. 3, pp. 185–195, 1996.
[53] H. Hong, K. Kohli, A. Trivedi, D. L. Johnson, and M. R.
Stallcup, “GRIP1, a novel mouse protein that serves as a
transcriptional coactivator in yeast for the hormone binding
domains of steroid receptors,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 93,
no. 10, pp. 4948–4952, 1996.16 PPAR Research
[54] H. Li, P. J. Gomes, and J. D. Chen, “RAC3, a steroid/nuclear
receptor-associated coactivator that is related to SRC-1 and
TIF2,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.94,no.16,pp.8479–8484,1997.
[ 5 5 ]S .L .A n z i c k ,J .K o n o n e n ,R .L .W a l k e re ta l . ,“ A I B 1 ,as t e r o i d
receptor coactivator ampliﬁed in breast and ovarian cancer,”
Science, vol. 277, no. 5328, pp. 965–968, 1997.
[56] J. C. Chrivia, R. P. S. Kwok, N. Lamb, M. Hagiwara, M.
R. Montminy, and R. H. Goodman, “Phosphorylated CREB
binds speciﬁcally to the nuclear protein CBP,” Nature, vol.
365, no. 6449, pp. 855–859, 1993.
[57] S. Malik and R. G. Roeder, “Dynamic regulation of pol II
transcription by the mammalian Mediator complex,” Trends
in Biochemical Sciences, vol. 30, no. 5, pp. 256–263, 2005.
[58] Y. Zhu, C. Qi, S. Jain, M. S. Rao, and J. K. Reddy, “Isolation
and characterization of PBP, a protein that interacts with
peroxisome proliferator-activated receptor,” The Journal of
BiologicalChemistry,vol.272,no.41,pp.25500–25506,1997.
[59] P. Puigserver, Z. Wu, C. W. Park, R. Graves, M. Wright, and
B. M. Spiegelman, “A cold-inducible coactivator of nuclear
receptors linked to adaptive thermogenesis,” Cell, vol. 92, no.
6, pp. 829–839, 1998.
[60] J. Lin, P. Puigserver, J. Donovan, P. Tarr, and B. M.
Spiegelman, “Peroxisome proliferator-activated receptor γ
coactivator 1β (PGC-1β), a novel PGC-1-related transcrip-
tion coactivator associated with host cell factor,” The Journal
of Biological Chemistry, vol. 277, no. 3, pp. 1645–1648, 2002.
[61] F. Caira, P. Antonson, M. Pelto-Huikko, E. Treuter, and J.-
˚ A. Gustafsson, “Cloning and characterization of RAP250, a
novel nuclear receptor coactivator,” The Journal of Biological
Chemistry, vol. 275, no. 8, pp. 5308–5317, 2000.
[62] Y. Zhu, L. Kan, C. Qi et al., “Isolation and characterization of
peroxisome proliferator-activated receptor (PPAR) interact-
ing protein (PRIP) as a coactivator for PPAR,” The Journal of
BiologicalChemistry,vol.275,no.18,pp.13510–13516,2000.
[63] S. Surapureddi, S. Yu, H. Bu et al., “Identiﬁcation of
a transcriptionally active peroxisome proliferator-activated
receptor α-interacting cofactor complex in rat liver and
characterization of PRIC285 as a coactivator,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 99, no. 18, pp. 11836–11841, 2002.
[64] S.Surapureddi,N.Viswakarma,S.Yu,D.Guo,M.S.Rao,and
J. K. Reddy, “PRIC320, a transcription coactivator, isolated
from peroxisome proliferator-binding protein complex,”
Biochemical and Biophysical Research Communications, vol.
343, no. 2, pp. 535–543, 2006.
[65] P. B. Becker and W. H¨ orz, “Atp-dependent nucleosome
remodeling,”AnnualReviewofBiochemistry,vol.71,pp.247–
273, 2002.
[66] K. E. Neely and J. L. Workman, “The complexity of
chromatin remodeling and its links to cancer,” Biochimica et
Biophysica Acta, vol. 1603, no. 1, pp. 19–29, 2002.
[67] S. Li, C. Liu, N. Li et al., “Genome-wide coactivation analysis
of PGC-1α identiﬁes BAF60a as a regulator of hepatic lipid
metabolism,” Cell Metabolism, vol. 8, no. 2, pp. 105–117,
2008.
[ 6 8 ]P . - W .H s i a o ,C .J .F r y e r ,K .W .T r o t t e r ,W .W a n g ,a n dT .
K. Archer, “BAF60a mediates critical interactions between
nuclear receptors and the BRG1 chromatin-remodeling
complex for transactivation,” Molecular and Cellular Biology,
vol. 23, no. 17, pp. 6210–6220, 2003.
[69] M.-B.Debril,L.Gelman,E.Fayard,J.-S.Annicotte,S.Rocchi,
and J. Auwerx, “Transcription factors and nuclear receptors
interact with the SWI/SNF complex through the BAF60c
subunit,” TheJournalof Biological Chemistry,vol.279, no.16,
pp. 16677–16686, 2004.
[70] Y. Zhu, C. Qi, W.-Q. Cao, A. V. Yeldandi, M. S. Rao, and J.
K. Reddy, “Cloning and characterization of PIMT, a protein
with a methyltransferase domain, which interacts with
and enhances nuclear receptor coactivator PRIP function,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 98, no. 18, pp. 10380–10385, 2001.
[71] D. Chen, H. Ma, H. Hong et al., “Regulation of transcription
by a protein methyltransferase,” Science, vol. 284, no. 5423,
pp. 2174–2177, 1999.
[72] T. Iwasaki, W. W. Chin, and L. Ko, “Identiﬁcation and
characterization of RRM-containing coactivator activator
(CoAA) as TRBP-interacting protein, and its splice variant as
a coactivator modulator (CoAM),” The Journal of Biological
Chemistry, vol. 276, no. 36, pp. 33375–33383, 2001.
[ 7 3 ]C . - X .Y u a n ,M .I t o ,J .D .F o n d e l l ,Z . - Y .F u ,a n dR .G .R o e d e r ,
“The TRAP220 component of a thyroid hormone receptor-
associated protein (TRAP) coactivator complex interacts
directly with nuclear receptors in a ligand-dependent fash-
ion,” Proceedings of the National Academy of Sciences of the
UnitedStatesofAmerica,vol.95,no.14,pp.7939–7944,1998.
[74] C. Rachez, B. D. Lemon, Z. Suldan et al., “Ligand-dependent
transcription activation by nuclear receptors requires the
DRIP complex,” Nature, vol. 398, no. 6730, pp. 824–828,
1999.
[75] J. K. Reddy, D. Guo, Y. Jia, S. Yu, and M. S. Rao, “Nuclear
receptor transcriptional coactivators in development and
metabolism,” Advances in Developmental Biology, vol. 16, pp.
389–420, 2006.
[76] S. Yu and J. K. Reddy, “Transcription coactivators for
peroxisome proliferator-activated receptors,” Biochimica et
Biophysica Acta, vol. 1771, no. 8, pp. 936–951, 2007.
[77] T.-P. Yao, S. P. Oh, M. Fuchs et al., “Gene dosage-dependent
embryonic development and proliferation defects in mice
lacking the transcriptional integrator p300,” Cell, vol. 93, no.
3, pp. 361–372, 1998.
[ 7 8 ]Y .Z h u ,C .Q i ,Y .J i a ,J .S .N y e ,M .S .R a o ,a n dJ .K .
Reddy, “Deletion of PBP/PARBP, the gene for nuclear recep-
tor coactivator peroxisome proliferator-activated receptor-
binding protein, results in embryonic lethality,” The Journal
of Biological Chemistry, vol. 275, no. 20, pp. 14779–14782,
2000.
[79] S. E. Crawford, C. Qi, P. Misra et al., “Defects of the
heart, eye, and megakaryocytes in peroxisome prolifera-
tor activator receptor-binding protein (PBP) null embryos
implicate GATA family of transcription factors,” The Journal
of Biological Chemistry, vol. 277, no. 5, pp. 3585–3592, 2002.
[80] E. L. Clark, A. Coulson, C. Dalgliesh et al., “The RNA
helicasep68isanovelandrogenreceptorcoactivatorinvolved
in splicing and is overexpressed in prostate cancer,” Cancer
Research, vol. 68, no. 19, pp. 7938–7946, 2008.
[ 8 1 ] H .K w o n ,A .N .I m b a l z a n o ,P .A .K h a v a ri ,R .E .K i n g s t o n ,a n d
M. R. Green, “Nucleosome disruption and enhancement of
activator binding by a human SW1/SNF complex,” Nature,
vol. 370, no. 6489, pp. 477–481, 1994.
[82] B. M. Spiegelman and R. Heinrich, “Biological control
through regulated transcriptional coactivators,” Cell, vol.
119, no. 2, pp. 157–167, 2004.
[83] S.-K. Lee, S. L. Anzick, J.-E. Choi et al., “A nuclear factor,
ASC-2, as a cancer-ampliﬁed transcriptional coactivator
essential for ligand-dependent transactivation by nuclear
receptors in vivo,” The Journal of Biological Chemistry, vol.
274, no. 48, pp. 34283–34293, 1999.PPAR Research 17
[84] M. A. Mahajan and H. H. Samuels, “A new family of
nuclear receptor coregulators that integrate nuclear receptor
signaling through CREB-binding protein,” Molecular and
Cellular Biology, vol. 20, no. 14, pp. 5048–5063, 2000.
[85] Y.-J. Zhu, S. E. Crawford, V. Stellmach et al., “Coactiva-
tor PRIP, the peroxisome proliferator-activated receptor-
interacting protein, is a modulator of placental, cardiac, hep-
atic, and embryonic development,” The Journal of Biological
Chemistry, vol. 278, no. 3, pp. 1986–1990, 2003.
[86] D. Li, Q. Kang, and D.-M. Wang, “Constitutive coactivator of
peroxisome proliferator-activated receptor (PPARγ), a novel
coactivator of PPARγ thatpromotesadipogenesis,”Molecular
Endocrinology, vol. 21, no. 10, pp. 2320–2333, 2007.
[87] G. Zhou, Y. Hashimoto, I. Kwak, S. Y. Tsai, and M.-J. Tsai,
“Role of the Steroid Receptor Coactivator SRC-3 in Cell
Growth,” Molecular and Cellular Biology, vol. 23, no. 21, pp.
7742–7755, 2003.
[88] J. Xu, R.-C. Wu, and B. W. O’Malley, “Normal and cancer-
related functions of the p160 steroid receptor co-activator
(SRC) family,” Nature Reviews Cancer, vol. 9, no. 9, pp. 615–
630, 2009.
[89] H.Zhang,X.Yi,X.Sunetal.,“Diﬀerentialgeneregulationby
the SRC family of coactivators,” Genes and Development, vol.
18, no. 14, pp. 1753–1765, 2004.
[ 9 0 ]J .X u ,Y .Q i u ,F .J .D e M a y o ,S .Y .T s a i ,M . - J .T s a i ,a n d
B. W. O’Malley, “Partial hormone resistance in mice with
disruption of the steroid receptor coactivator-1 (SRC-1)
gene,” Science, vol. 279, no. 5358, pp. 1922–1925, 1998.
[91] P.Puigserver,G.Adelmant,Z.Wuetal.,“ActivationofPPARγ
coactivator-1 through transcription factor docking,” Science,
vol. 286, no. 5443, pp. 1368–1371, 1999.
[ 9 2 ]C .Q i ,Y .Z h u ,J .P a ne ta l . ,“ M o u s es t e r o i dr e c e p t o r
coactivator-1 is not essential for peroxisome proliferator-
activated receptor α-regulated gene expression,” Proceedings
of the National Academy of Sciences of the United States of
America, vol. 96, no. 4, pp. 1585–1590, 1999.
[93] J. Xu, L. Liao, G. Ning, H. Yoshida-Komiya, C. Deng,
a n dB .W .O ’ M a l l e y ,“ T h es t e r o i dr e c e p t o rc o a c t i v a t o r
SRC-3 (P/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for
normal growth, puberty, female reproductive function, and
mammary gland development,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 97,
no. 12, pp. 6379–6384, 2000.
[94] M. Gehin, M. Mark, C. Dennefeld, A. Dierich, H. Grone-
meyer, and P. Chambon, “The function of TIF2/GRIP1 in
mouse reproduction is distinct from those of SRC-1 and
p/CIP,” Molecular and Cellular Biology, vol. 22, no. 16, pp.
5923–5937, 2002.
[95] F. Picard, M. G´ ehin, J.-S. Annicotte et al., “SRC-1 and TIF2
control energy balance between white and brown adipose
tissues,” Cell, vol. 111, no. 7, pp. 931–941, 2002.
[ 9 6 ] R .E .W e i s s ,J .X u ,G .N i n g ,J .P o h l e n z ,B .W .O ’ M a l l e y ,a n dS .
Refetoﬀ, “Mice deﬁcient in the steroid receptor co-activator
1 (SRC-1) are resistant to thyroid hormone,” EMBO Journal,
vol. 18, no. 7, pp. 1900–1904, 1999.
[97] P.Puigserver,G.Adelmant,Z.Wuetal.,“ActivationofPPARγ
coactivator-1 through transcription factor docking,” Science,
vol. 286, no. 5443, pp. 1368–1371, 1999.
[98] J.-W. Jeong, I. Kwak, K. Y. Lee et al., “The genomic analysis
of the impact of steroid receptor coactivators ablation on
hepatic metabolism,” Molecular Endocrinology, vol. 20, no. 5,
pp. 1138–1152, 2006.
[99] A. R. Chopra, J.-F. Louet, P. Saha et al., “Absence of the SRC-
2 coactivator results in a glycogenopathy resembling Von
Gierke’s disease,” Science, vol. 322, no. 5906, pp. 1395–1399,
2008.
[100] M. Mark, H. Yoshida-Komiya, M. Gehin et al., “Partially
redundant functions of SRC-1 and TIF2 in postnatal survival
and male reproduction,” Proceedings of the National Academy
of Sciences of the United States of America, vol. 101, no. 13, pp.
4453–4458, 2004.
[101] J.-F. Louet, A. Coste, L. Amazit et al., “Oncogenic steroid
receptor coactivator-3 is a key regulator of the white adi-
pogenic program,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 103, no. 47, pp.
17868–17873, 2006.
[102] J.-F. Louet and B. W. O’Malley, “Coregulators in adipogen-
esis: what could we learn from the SRC (p160) coactivator
family?” Cell Cycle, vol. 6, no. 20, pp. 2448–2452, 2007.
[103] R.Eckner,M.E.Ewen,D.Newsomeetal.,“Molecularcloning
and functional analysis of the adenovirus E1A- associated
300-kD protein (p300) reveals a protein with properties of a
transcriptional adaptor,” Genes and Development, vol. 8, no.
8, pp. 869–884, 1994.
[104] D. Chekravarti, V. J. LaMorte, M. C. Nelson et al., “Role of
CBP/P300 in nuclear receptor signalling,” Nature, vol. 383,
no. 6595, pp. 99–103, 1996.
[105] Z. Arany, W. R. Sellers, D. M. Livingston, and R. Eckner,
“E1A-associated p300 and CREB-associated CBP belong to
a conserved family of coactivators,” Cell, vol. 77, no. 6, pp.
799–800, 1994.
[106] C. L. Smith, S. A. O˜ nate, M.-J. Tsai, and B. W. O’Malley,
“CREB binding protein acts synergistically with steroid
receptor coactivator-1 to enhance steroid receptor-
dependent transcription,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 93,
no. 17, pp. 8884–8888, 1996.
[107] J. Torchia, D. W. Rose, J. Inostroza et al., “The transcriptional
co-activatorp/CIPbindsCBPandmediatesnuclear-receptor
function,” Nature, vol. 387, no. 6634, pp. 677–684, 1997.
[108] L. Waters, B. Yue, V. Veverka et al., “Structural diversity
in p160/CREB-binding protein coactivator complexes,” The
Journal of Biological Chemistry, vol. 281, no. 21, pp. 14787–
14795, 2006.
[109] A. Polesskaya, I. Naguibneva, A. Duquet, E. Bengal, P. Robin,
and A. Harel-Bellan, “Interaction between acetylated MyoD
and the bromodomain of CBP and/or p300,” Molecular and
Cellular Biology, vol. 21, no. 16, pp. 5312–5320, 2001.
[110] P. Dowell, J. E. Ishmael, D. Avram, V. J. Peterson, D. J.
Nevrivy,andM.Leid,“p300functionsasacoactivatorforthe
peroxisome proliferator- activated receptor α,” The Journal of
BiologicalChemistry,vol.272,no.52,pp.33435–33443,1997.
[111] K. Mochizuki, K. Suruga, N. Sakaguchi, S. Takase, and T.
Goda, “Major intestinal coactivator p300 strongly activates
peroxisome proliferator-activated receptor in intestinal cell
line, Caco-2,” Gene, vol. 291, no. 1-2, pp. 271–277, 2002.
[112] K. Mochizuki, T. Suzuki, and T. Goda, “PPARα and PPARδ
transactivity and p300 binding activity induced by arachi-
donic acid in colorectal cancer cell line Caco-2,” Journal of
Nutritional Science and Vitaminology, vol. 54, no. 4, pp. 298–
302, 2008.
[113] C. Dreyer, H. Keller, A. Mahfoudi, V. Laudet, G. Krey, and W.
Wahli, “Positive regulation of the peroxisomal β-oxidation
pathway by fatty acids through activation of peroxisome
proliferator-activated receptors (PPAR),” Biology of the Cell,
vol. 77, no. 1, pp. 67–76, 1993.
[114] S. A. Kliewer, S. S. Sundseth, S. A. Jones et al., “Fatty
acidsandeicosanoidsregulategeneexpressionthroughdirect18 PPAR Research
interactionswithperoxisomeproliferator-activatedreceptors
αandγ,” ProceedingsoftheNationalAcademyofSciencesofthe
United States of America, vol. 94, no. 9, pp. 4318–4323, 1997.
[115] M. J. Barber´ a, A. Schl¨ uter, N. Pedraza, R. Iglesias, F.
Villarroya, and M. Giralt, “Peroxisome proliferator-activated
receptor α activates transcription of the brown fat uncou-
pling protein-1 gene. A link between regulation of the
thermogenic and lipid oxidation pathways in the brown fat
cell,” The Journal of Biological Chemistry, vol. 276, no. 2, pp.
1486–1493, 2001.
[116] L. Gelman, G. Zhou, L. Fajas, E. Rasp´ e, J.-C. Fruchart, and
J. Auwerx, “p300 Interacts with the N- and C-terminal part
ofPPARγ2inaligand-independentand-dependentmanner,
respectively,” TheJournalofBiologicalChemistry,vol.274,no.
12, pp. 7681–7688, 1999.
[117] S. Chen, B. A. Johnson, Y. Li et al., “Both coactivator LXXLL
motif-dependent and -independent interactions are required
for peroxisome proliferator-activated receptor γ (PPARγ)
function,” The Journal of Biological Chemistry, vol. 275, no.
6, pp. 3733–3736, 2000.
[118] A. Bugge, L. Grøntved, M. M. Aagaard, R. Borup, and S.
Mandrup, “The PPARγ2 A/B-domain plays a gene-speciﬁc
role in transactivation and cofactor recruitment,” Molecular
Endocrinology, vol. 23, no. 6, pp. 794–808, 2009.
[119] J. Mizukami and T. Taniguchi, “The antidiabetic agent thia-
zolidinedione stimulates the interaction between PPARγ and
CBP,” Biochemical and Biophysical Research Communications,
vol. 240, no. 1, pp. 61–64, 1997.
[120] K. Tateishi, Y. Okada, E. M. Kallin, and Y. Zhang, “Role of
Jhdm2a in regulating metabolic gene expression and obesity
resistance,” Nature, vol. 458, no. 7239, pp. 757–761, 2009.
[121] C. Qi, S. Surapureddi, Y. -J. Zhu et al., “Transcriptional coac-
tivator PRIP, the peroxisome proliferator-activated receptor
γ (PPARγ)-interacting protein, is required for PPARγ-
mediated adipogenesis,” The Journal of Biological Chemistry,
vol. 278, no. 28, pp. 25281–25284, 2003.
[122] Y.-M. Sue, C.-P. Chung, H. Lin et al., “PPARδ-mediated
p21/p27 induction via increased CREB-binding protein
nuclear translocation in beraprost-induced antiproliferation
of murine aortic smooth muscle cells,” American Journal of
Physiology, vol. 297, no. 2, pp. C321–C329, 2009.
[123] A. M. N¨ a¨ a r ,P .A .B e a u r a n g ,S .Z h o u ,S .A b r a h a m ,W .
Solomon, and R. Tjian, “Composite co-activator ARC medi-
ates chromatin-directed transcriptional activation,” Nature,
vol. 398, no. 6730, pp. 828–832, 1999.
[124] R. D. Kornberg, “Mediator and the mechanism of transcrip-
tional activation,” Trends in Biochemical Sciences, vol. 30, no.
5, pp. 235–239, 2005.
[125] A. B. Hittelman, D. Burakov, J. A. I˜ niguez-Lluh´ ı, L. P.
Freedman, and M. J. Garabedian, “Diﬀerential regulation of
glucocorticoid receptor transcriptional activation via AF-1-
associatedproteins,”EMBOJournal,vol.18,no.19,pp.5380–
5388, 1999.
[126] P. Dran´ e, M. Barel, M. Balbo, and R. Frade, “Identiﬁcation of
RB18A, a 205 kDa new p53 regulatory protein which shares
antigenic and functional properties with p53,” Oncogene, vol.
15, no. 25, pp. 3013–3024, 1997.
[127] S. Lottin-Divoux, M. Barel, and R. Frade, “RB18A enhances
expression of mutant p53 protein in human cells,” FEBS
Letters, vol. 579, no. 11, pp. 2323–2326, 2005.
[128] D.F.Gordon,E.A.Tucker,K.Tundwal,H.Hall,W.M.Wood,
and E. C. Ridgway, “MED220/thyroid receptor-associated
protein 220 functions as a transcriptional coactivator with
pit-1 and GATA-2 on the thyrotropin-β promoter in thy-
rotropes,” Molecular Endocrinology, vol. 20, no. 5, pp. 1073–
1089, 2006.
[129] H. Li, P. Gade, S. C. Nallar et al., “The Med1 subunit of
transcriptional mediator plays a central role in regulating
CCAAT/enhancer-binding protein-β-driven transcription in
responsetointerferon-γ,” TheJournalofBiologicalChemistry,
vol. 283, no. 19, pp. 13077–13086, 2008.
[130] M. Belakavadi and J. D. Fondell, “Role of the Mediator
complex in nuclear hormone receptor signaling,” Reviews of
Physiology, Biochemistry and Pharmacology, vol. 156, pp. 23–
43, 2006.
[131] P. Misra, E. D. Owuor, W. Li et al., “Phosphorylation of
transcriptional coactivator peroxisome proliferator-activated
receptor(PPAR)-bindingprotein(PBP).Stimulationoftran-
scriptional regulation by mitogen-activated protein kinase,”
The Journal of Biological Chemistry, vol. 277, no. 50, pp.
48745–48754, 2002.
[132] M. Belakavadi, P. K. Pandey, R. Vijayvargia, and J. D.
Fondell, “MED1 phosphorylation promotes its association
with mediator: implications for nuclear receptor signaling,”
MolecularandCellularBiology,vol.28,no.12,pp.3932–3942,
2008.
[133] S. Jain, S. Pulikuri, Y. Zhu et al., “Diﬀerential expression
of the peroxisome proliferator-activated receptor γ (PPARγ)
and its coactivators steroid receptor coactivator-1 and PPAR-
bindingproteinPBPinthebrownfat,urinarybladder,colon,
and breast of the mouse,” American Journal of Pathology, vol.
153, no. 2, pp. 349–354, 1998.
[134] J.-F. Mouillet, T. Chu, D. M. Nelson, T. Mishima, and
Y. Sadovsky, “MiR-205 silences MED1 in hypoxic primary
humantrophoblasts,”FASEBJournal,vol.24,no.6,pp.2030–
2039, 2010.
[135] Y. Barak, M. C. Nelson, E. S. Ong et al., “PPARγ is required
for placental, cardiac, and adipose tissue development,”
Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999.
[136] M. Ito, C.-X. Yuan, H. J. Okano, R. B. Darnell, and R. G.
Roeder, “Involvement of the TRAP220 component of the
TRAP/SMCC coactivator complex in embryonic develop-
mentandthyroidhormoneaction,”MolecularCell,vol.5,no.
4, pp. 683–693, 2000.
[137] C. Landles, S. Chalk, J. H. Steel et al., “The thyroid
hormonereceptor-associated protein TRAP220isrequired at
distinct embryonic stages in placental, cardiac, and hepatic
development,” Molecular Endocrinology, vol. 17, no. 12, pp.
2418–2435, 2003.
[138] K. Ge, Y.-W. Cho, H. Guo et al., “Alternative mechanisms
by which mediator subunit MED1/TRAP220 regulates per-
oxisome proliferator-activated receptor γ-stimulated adipo-
genesis and target gene expression,” Molecular and Cellular
Biology, vol. 28, no. 3, pp. 1081–1091, 2008.
[139] K. Ge, M. Guermah, C.-X. Yuan et al., “Transcription
coactivator TRAP220 is required for PPARγ2-stimulated
adipogenesis,” Nature, vol. 417, no. 6888, pp. 563–567, 2002.
[140] Y. Jia, C. Qi, P. Kashireddi et al., “Transcription coactivator
PBP, the peroxisome proliferator-activated receptor (PPAR)-
binding protein, is required for PPARα-regulated gene
expression in liver,” The Journal of Biological Chemistry, vol.
279, no. 23, pp. 24427–24434, 2004.
[141] W. Chen, X. Zhang, K. Birsoy, and R. G. Roeder, “A muscle-
speciﬁc knockout implicates nuclear receptor coactivator
MED1 in the regulation of glucose and energy metabolism,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 107, no. 22, pp. 10196–10201, 2010.PPAR Research 19
[142] K. Matsumoto, S. Yu, Y. Jia et al., “Critical role for transcrip-
tion coactivator Peroxisome Proliferator- activated Receptor
(PPAR)-binding protein/TRAP220 in liver regeneration and
PPARα ligand-induced liver tumor development,” The Jour-
nalofBiologicalChemistry,vol.282,no.23,pp.17053–17060,
2007.
[143] K. Matsumoto, J. Huang, N. Viswakarma et al., “Tran-
scription coactivator PBP/MED1-deﬁcient hepatocytes are
not susceptible to diethylnitrosamine-induced hepatocar-
cinogenesis in the mouse,” Carcinogenesis,v o l .3 1 ,n o .2 ,p p .
318–325, 2009.
[144] Y. Jia, G. L. Guo, S. Surapureddi et al., “Transcription coac-
tivator peroxisome proliferator-activated receptor-binding
protein/mediator1deﬁciencyabrogatesacetaminophenhep-
atotoxicity,” Proceedings of the National Academy of Sciences
of the United States of America, vol. 102, no. 35, pp. 12531–
12536, 2005.
[145] Y. Jia, N. Viswakarma, T. Fu et al., “Conditional abla-
tion of mediator subunit MED1 (MED1/PPARBP) gene
in mouse liver attenuates glucocorticoid receptor agonist
dexamethasone-induced hepatic steatosis,” Gene Expression,
vol. 14, no. 5, pp. 291–306, 2009.
[146] Y. Jia, C. Qi, Z. Zhang, Y. T. Zhu, S. M. Rao, and Y.-
J. Zhu, “Peroxisome proliferator-activated receptor-binding
protein null mutation results in defective mammary gland
development,” The Journal of Biological Chemistry, vol. 280,
no. 11, pp. 10766–10773, 2005.
[147] Y. T. Zhu, Y. Jia, L. Hu et al., “Peroxisome-proliferator-
activated receptor-binding protein (PBP) is essential for the
growth of active Notch4-immortalized mammary epithelial
cells by activating SOX10 expression,” Biochemical Journal,
vol. 425, no. 2, pp. 435–444, 2010.
[148] A. Kourtidis, R. Jain, R. D. Carkner, C. Eifert, M. J. Brosnan,
and D. S. Conklin, “An RNA interference screen identiﬁes
metabolic regulators NR1D1 and PBP as novel survival
factors for breast cancer cells with the ERBB2 signature,”
Cancer Research, vol. 70, no. 5, pp. 1783–1792, 2010.
[149] R. Vijayvargia, M. S. May, and J. D. Fondell, “A coregulatory
role for the mediator complex in prostate cancer cell
proliferation and gene expression,” Cancer Research, vol. 67,
no. 9, pp. 4034–4041, 2007.
[150] J. De La Croix Ndong, D. Jean, N. Rousselet, and R.
Frade,“Down-regulationoftheexpressionofRB18A/MED1,
a cofactor of transcription, triggers strong tumorigenic
phenotype of human melanoma cells,” International Journal
of Cancer, vol. 124, no. 11, pp. 2597–2606, 2009.
[151] X. Zhang, A. Krutchinsky, A. Fukuda et al.,
“MED1/TRAP220 exists predominantly in a TRAP/Mediator
subpopulation enriched in RNA polymerase II and is
required for ER-mediated transcription,” Molecular Cell, vol.
19, no. 1, pp. 89–100, 2005.
[152] U. Andersson and R. C. Scarpulla, “PGC-1-related coac-
tivator, a novel, serum-inducible coactivator of nuclear
respiratory factor 1-dependent transcription in mammalian
cells,” Molecular and Cellular Biology, vol. 21, no. 11, pp.
3738–3749, 2001.
[153] J. Lin, P. T. Tarr, R. Yang et al., “PGC-1β in the regulation
of hepatic glucose and energy metabolism,” The Journal of
BiologicalChemistry,vol.278,no.33,pp.30843–30848,2003.
[154] R. B. Vega, J. M. Huss, and D. P. Kelly, “The coactivator PGC-
1 cooperates with peroxisome proliferator-activated receptor
α in transcriptional control of nuclear genes encoding
mitochondrial fatty acid oxidation enzymes,” Molecular and
Cellular Biology, vol. 20, no. 5, pp. 1868–1876, 2000.
[155] D.Knutti,A.Kaul,andA.Kralli,“Atissue-speciﬁccoactivator
of steroid receptors, identiﬁed in a functional genetic screen,”
Molecular and Cellular Biology, vol. 20, no. 7, pp. 2411–2422,
2000.
[156] Y. Zhang, L. W. Castellani, C. J. Sinal, F. J. Gonzalez, and
P. A. Edwards, “Peroxisome proliferator-activated receptor-
γ coactivator 1α (PGC-1α) regulates triglyceride metabolism
by activation of the nuclear receptor FXR,” Genes and
Development, vol. 18, no. 2, pp. 157–169, 2004.
[157] J. Lin, R. Yang, P. T. Tarr et al., “Hyperlipidemic eﬀects of
dietarysaturatedfatsmediatedthroughPGC-1βcoactivation
of SREBP,” Cell, vol. 120, no. 2, pp. 261–273, 2005.
[158] J. G. Duncan, J. L. Fong, D. M. Medeiros, B. N. Finck, and
D. P. Kelly, “Insulin-resistant heart exhibits a mitochondrial
biogenic response driven by the peroxisome proliferator-
activated receptor-α/PGC-1α gene regulatory pathway,” Cir-
culation, vol. 115, no. 7, pp. 909–917, 2007.
[159] S.-H. Koo, H. Satoh, S. Herzig et al., “PGC-1 promotes
insulin resistance in liver through PPAR-α-dependent induc-
tion of TRB-3,” Nature Medicine, vol. 10, no. 5, pp. 530–534,
2004.
[160] Y. Li, A. Kovach, K. Suino-Powell, D. Martynowski, and H.
E. Xu, “Structural and biochemical basis for the binding
selectivity of peroxisome proliferator-activated receptor γ to
PGC-1α,” The Journal of Biological Chemistry, vol. 283, no.
27, pp. 19132–19139, 2008.
[161] E. Hondares, O. Mora, P. Yubero et al., “Thiazolidine-
diones and rexinoids induce peroxisome proliferator-
activated receptor-coactivator (PGC)-1α gene transcription:
an autoregulatory loop controls PGC-1α expression in
adipocytes via peroxisome proliferator-activated receptor-γ
coactivation,” Endocrinology, vol. 147, no. 6, pp. 2829–2838,
2006.
[162] T.H.Røst,L.L.HauganMoi,K.Berge,B.Staels,G.Mellgren,
and R. K. Berge, “A pan-PPAR ligand induces hepatic fatty
acid oxidation in PPARα−/− mice possibly through PGC-
1 mediated PPARδ coactivation,” Biochimica et Biophysica
Acta, vol. 1791, no. 11, pp. 1076–1083, 2009.
[163] S. Kleiner, V. Nguyen-Tran, O. Bar´ e, X. Huang, B. Spiegel-
man, and Z. Wu, “PPARδ agonism activates fatty acid
oxidation via PGC-1α but does not increase mitochondrial
gene expression and function,” The Journal of Biological
Chemistry, vol. 284, no. 28, pp. 18624–18633, 2009.
[164] T. C. Leone, J. J. Lehman, B. N. Finck et al., “PGC-
1alpha deﬁciency causes multi-system energy metabolic
derangements: muscle dysfunction, abnormal weight control
and hepatic steatosis,” PLoS Biology, vol. 3, no. 4, p. e101,
2005.
[165] Z. Arany, H. He, J. Lin et al., “Transcriptional coactivator
PGC-1α controls the energy state and contractile function of
cardiac muscle,” Cell Metabolism, vol. 1, no. 4, pp. 259–271,
2005.
[166] J. J. Lehman, S. Boudina, N. H. Banke et al., “The tran-
scriptional coactivator PGC-1α is essential for maximal and
eﬃcient cardiac mitochondrial fatty acid oxidation and lipid
homeostasis,” American Journal of Physiology, vol. 295, no. 1,
pp. H185–H196, 2008.
[167] C.J.Lelliott,A.Ljungberg,A.Ahnmarketal.,“HepaticPGC-
1β overexpression induces combined hyperlipidemia and
modulates the response to PPARα activation,” Arterioscle-
rosis, Thrombosis, and Vascular Biology, vol. 27, no. 12, pp.
2707–2713, 2007.
[168] J. Sonoda, I. R. Mehl, L.-W. Chong, R. R. Nofsinger, and
R. M. Evans, “PGC-1β controls mitochondrial metabolism20 PPAR Research
to modulate circadian activity, adaptive thermogenesis, and
hepatic steatosis,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 104, no. 12, pp.
5223–5228, 2007.
[169] Y.-H.Goo,Y.ChangSohn,D.-H.Kimetal.,“Activatingsignal
cointegrator 2 belongs to a novel steady-state complex that
contains a subset of trithorax group proteins,” Molecular and
Cellular Biology, vol. 23, no. 1, pp. 140–149, 2003.
[170] Y. Zhu, C. Qi, S. Jain, et al., “Amplication and overexpression
of peroxisome proliferator-activated receptor binding pro-
tein (PBP/PPARBP) gene in breast cancer,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 96, no. 19, pp. 10848–10853, 1999.
[171] Y. T. Zhu, L. Hu, C. Qi, and Y.-J. Zhu, “PRIP promotes tumor
formation through enhancing serum-responsive factor-
mediated FOS expression,” The Journal of Biological Chem-
istry, vol. 284, no. 21, pp. 14485–14492, 2009.
[172] S.-W. Kim, K. Park, E. Kwak et al., “Activating signal
cointegrator 2 required for liver lipid metabolism mediated
b yl i v e rXr e c e p t o r si nm i c e , ”Molecular and Cellular Biology,
vol. 23, no. 10, pp. 3583–3592, 2003.
[173] S.-Q.Kuang,L.Liao,H.Zhangetal.,“Deletionofthecancer-
ampliﬁed coactivator AIB3 results in defective placentation
and embryonic lethality,” The Journal of Biological Chemistry,
vol. 277, no. 47, pp. 45356–45360, 2002.
[174] Q. Li, M.-J. Chu, and J. Xu, “Tissue- and nuclear receptor-
speciﬁc function of the C-terminal LXXLL motif of coacti-
vator NCoA6/AIB3 in mice,” Molecular and Cellular Biology,
vol. 27, no. 23, pp. 8073–8086, 2007.
[175] S.-Y. Yeom, G. H. Kim, C. H. Kim et al., “Regulation
of insulin secretion and β-cell mass by activating signal
cointegrator 2,” Molecular and Cellular Biology, vol. 26, no.
12, pp. 4553–4563, 2006.
[176] M. A. Mahajan and H. H. Samuels, “Nuclear receptor
coactivator/coregulator NCoA6(NRC) is a pleiotropic coreg-
ulator involved in transcription, cell survival, growth and
development,” Nuclear Receptor Signaling, vol. 6, p. e002,
2008.
[177] H. Zhang, L. Liao, S.-Q. Kuang, and J. Xu, “Spatial distri-
bution of the messenger ribonucleic acid and protein of the
nuclear receptor coactivator, ampliﬁed in breast cancer-3, in
mice,” Endocrinology, vol. 144, no. 4, pp. 1435–1443, 2003.
[178] P. Antonson, G. U. Schuster, L. Wang et al., “Inactivation
of the nuclear receptor coactivator RAP250 in mice results
in placental vascular dysfunction,” Molecular and Cellular
Biology, vol. 23, no. 4, pp. 1260–1268, 2003.
[179] M. A. Mahajan and H. H. Samuels, “Nuclear hormone
receptor coregulator: role in hormone action, metabolism,
growth, and development,” Endocrine Reviews, vol. 26, no. 4,
pp. 583–597, 2005.
[180] S.-K. Lee, S.-Y. Na, S.-Y. Jung et al., “Activating protein-1,
nuclear factor-κB, and serum response factor as novel target
molecules of the cancer-ampliﬁed transcription coactivator
ASC-2,” Molecular Endocrinology, vol. 14, no. 6, pp. 915–925,
2000.
[181] H. Zhang, S.-Q. Kuang, L. Liao, S. Zhou, and J. Xu, “Haploid
inactivation of the ampliﬁed-in-breast cancer 3 coactivator
reduces the inhibitory eﬀect of peroxisome proliferator-
activated receptor γ and retinoid X receptor on cell prolif-
eration and accelerates polyoma middle-T antigen-induced
mammary tumorigenesis in mice,” Cancer Research, vol. 64,
no. 19, pp. 7169–7177, 2004.
[182] J. Sarkar, C. Qi, D. Guo et al., “Transcription coacti-
vator PRIP, the peroxisome proliferator-activated receptor
(PPAR)-interacting protein, is redundant for the function
of nuclear receptors PPARα and CAR, the constitutive
androstanereceptor,inmouseliver,”GeneExpression,vol.13,
no. 4-5, pp. 255–269, 2007.
[183] T. Tomaru, T. Satoh, S. Yoshino et al., “Isolation and
characterization of a transcriptional cofactor and its novel
isoformthatbindthedeoxyribonucleic acid-bindingdomain
of peroxisome proliferator-activated receptor-γ,” Endocrinol-
ogy, vol. 147, no. 1, pp. 377–388, 2006.
[184] R.S.SavkurandT.P.Burris,“ThecoactivatorLXXLLnuclear
receptor recognition motif,” J o u r n a lo fP e p t i d eR e s e a r c h , vol.
63, no. 3, pp. 207–212, 2004.
[185] N. Viswakarma, K. Matsumoto, Y. Jia, M. S. Rao, and J. K.
Reddy, “Mice lacking transcription cofactor PRIC285 reveal
attenuation of liver regeneration but are viable and develop
normally,” FASEB Journal, vol. 23, p. 117.6, 2009.
[186] I. Shur, R. Socher, and D. Benayahu, “In vivo association of
CReMM/CHD9 with promoters in osteogenic cells,” Journal
of Cellular Physiology, vol. 207, no. 2, pp. 374–378, 2006.
[187] C. G. A. Marfella and A. N. Imbalzano, “The Chd family of
chromatin remodelers,” Mutation Research, vol. 618, no. 1-2,
pp. 30–40, 2007.
[188] J. A. Hall and P. T. Georgel, “CHD proteins: a diverse family
withstrongties,”Biochemistry and Cell Biology, vol. 85, no. 4,
pp. 463–476, 2007.
[189] V. Delmas, D. G. Stokes, and R. P. Perry, “A mammalian
DNA-binding protein that contains a chromodomain and
an SNF2/SW12-like helicase domain,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 90, no. 6, pp. 2414–2418, 1993.
[190] T. Woodage, M. A. Basrai, A. D. Baxevanis, P. Hieter, and F.
S. Collins, “Characterization of the CHD family of proteins,”
Proceedings of the National Academy of Sciences of the United
States of America, vol. 94, no. 21, pp. 11472–11477, 1997.
[191] I. Shur and D. Benayahu, “Characterization and functional
analysis of CReMM, a novel chromodomain helicase DNA-
binding protein,” Journal of Molecular Biology, vol. 352, no. 3,
pp. 646–655, 2005.
[192] H. Chiba, M. Muramatsu, A. Nomoto, and H. Kato, “Two
humanhomologuesofSaccharomycescerevisiaeSWI2/SNF2
and Drosophila brahma are transcriptional coactivators
cooperating with the estrogen receptor and the retinoic acid
receptor,” Nucleic Acids Research, vol. 22, no. 10, pp. 1815–
1820, 1994.
[193] T. Tsukiyama, “The in vivo functions of ATP-dependent
chromatin-remodelling factors,” Nature Reviews Molecular
Cell Biology, vol. 3, no. 6, pp. 422–429, 2002.
[194] C. L. Peterson, “Chromatin remodeling: nucleosomes
bulging at the seams,” Current Biology, vol. 12, no. 7, pp.
R245–R247, 2002.
[195] T. ˚ A. Pedersen, E. Kowenz-Leutz, A. Leutz, and C. Nerlov,
“Cooperation between C/EBPα TBP/TFIIB and SWI/SNF
recruiting domains is required for adipocyte diﬀerentiation,”
Genes and Development, vol. 15, no. 23, pp. 3208–3216, 2001.
[196] B. Lemon, C. Inouye, D. S. King, and R. Tjian, “Selectivity of
chromatin-remodelling cofactors for ligand-activated tran-
scription,” Nature, vol. 414, no. 6866, pp. 924–928, 2001.
[197] N. Salma, H. Xiao, E. Mueller, and A. N. Imbalzano, “Tem-
poral recruitment of transcription factors and SWI/SNF
chromatin-remodeling enzymes during adipogenic induc-
tion of the peroxisome proliferator-activated receptor γ
nuclear hormone receptor,” Molecular and Cellular Biology,
vol. 24, no. 11, pp. 4651–4663, 2004.PPAR Research 21
[198] W. Wang, J. Cˆ ot´ e, Y. Xue et al., “Puriﬁcation and biochemical
heterogeneity of the mammalian SWI-SNF complex,” EMBO
Journal, vol. 15, no. 19, pp. 5370–5382, 1996.
[199] Z. Nie, Y. Xue, D. Yang et al., “A speciﬁcity and targeting
subunit of a human SWI/SNF family-related chromatin-
remodelingcomplex,”MolecularandCellularBiology,vol.20,
no. 23, pp. 8879–8888, 2000.
[200] J. A. Martens and F. Winston, “Recent advances in under-
standing chromatin remodeling by Swi/Snf complexes,”
Current Opinion in Genetics and Development,v o l .1 3 ,n o .2 ,
pp. 136–142, 2003.
[201] P. Misra, C. Qi, S. Yu et al., “Interaction of PIMT with
transcriptional coactivators CBP, p300, and PBP diﬀerential
role in transcriptional regulation,” The Journal of Biological
Chemistry, vol. 277, no. 22, pp. 20011–20019, 2002.
[202] J. Mouaikel, C. Verheggen, E. Bertrand, J. Tazi, and R.
Bordonn´ e, “Hypermethylation of the cap structure of both
yeast snRNAs and snoRNAs requires a conserved methyl-
transferase that is localized to the nucleolus,” Molecular Cell,
vol. 9, no. 4, pp. 891–901, 2002.
[203] O. Komonyi, G. P´ apai, I. Enunlu et al., “DTL, the Drosophila
homolog of PIMT/Tgs1 nuclear receptor coactivator-
interacting protein/RNA methyltransferase, has an essential
roleindevelopment,”TheJournalofBiologicalChemistry,vol.
280, no. 13, pp. 12397–12404, 2005.
[204] I. En¨ unl¨ u, G. P´ apai, I. Cserp´ an, A. Udvardy, K.-T. Jeang,
a n dI .B o r o s ,“ D i ﬀerent isoforms of PRIP-interacting protein
with methyltransferase domain/trimethylguanosine synthase
localizes to the cytoplasm and nucleus,” Biochemical and
Biophysical Research Communications, vol. 309, no. 1, pp. 44–
51, 2003.
[205] Y. Jia, N. Viswakarma, K. Matsumoto, S. R. Pyper, M. S.
Rao, and J. K. Reddy, “Early embryonic lethality of mice
withdisruptedtranscriptioncofactorPIMT/NCoA6IPgene,”
FASEB Journal, vol. 23, p. 739.6, 2009.
[206] M. R. Stallcup, J. H. Kim, C. Teyssier, Y.-H. Lee, H. Ma,
and D. Chen, “The roles of protein-protein interactions
and protein methylation in transcriptional activation by
nuclear receptors and their coactivators,” Journal of Steroid
BiochemistryandMolecularBiology,vol.85,no.2–5,pp.139–
145, 2003.
[207] J. M. Aletta, T. R. Cimato, and M. J. Ettinger, “Protein methy-
lation: a signal event in post-translational modiﬁcation,”
Trends in BiochemicalSciences,vol. 23, no. 3, pp. 89–91, 1998.
[208] N. Yadav, D. Cheng, S. Richard et al., “CARM1 promotes
adipocyte diﬀerentiation by coactivating PPARγ,” EMBO
Reports, vol. 9, no. 2, pp. 193–198, 2008.
[209] M. Chevillard-Briet, D. Trouche, and L. Vandel, “Control of
CBP co-activating activity by arginine methylation,” EMBO
Journal, vol. 21, no. 20, pp. 5457–5466, 2002.
[210] W. Xu, H. Chen, K. Du et al., “A transcriptional switch
mediated by cofactor methylation,” Science, vol. 294, no.
5551, pp. 2507–2511, 2001.
[211] Y.-H. Lee, S. A. Coonrod, W. L. Kraus, M. A. Jelinek,
and M. R. Stallcup, “Regulation of coactivator complex
assembly and function by protein arginine methylation and
demethylimination,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 102, no. 10, pp.
3611–3616, 2005.
[212] C. Teyssier, D. Chen, and M. R. Stallcup, “Requirement for
multiple domains of the protein arginine methyltransferase
CARM1initstranscriptionalcoactivatorfunction,”TheJour-
nalofBiologicalChemistry,vol.277,no.48,pp. 46066–46072,
2002.
[213] M. T. Bedford, “Arginine methylation at a glance,” Journal of
Cell Science, vol. 120, no. 24, pp. 4243–4246, 2007.
[214] Q. Feng, P. Yi, J. Wong, and B. W. O’Malley, “Signaling
within a coactivator complex: methylation of SRC-3/AIB1 is
a molecular switch for complex disassembly,” Molecular and
Cellular Biology, vol. 26, no. 21, pp. 7846–7857, 2006.
[215] N. Yadav, J. Lee, J. Kim et al., “Speciﬁc protein methylation
defects and gene expression perturbations in coactivator-
associated arginine methyltransferase 1-deﬁcient mice,” Pro-
ceedings of the National Academy of Sciences of the United
States of America, vol. 100, no. 11, pp. 6464–6468, 2003.
[216] D. Auboeuf, D. H. Dowhan, X. Li et al., “CoAA, a nuclear
receptorcoactivatorproteinattheinterfaceoftranscriptional
coactivation and RNA splicing,” Molecular and Cellular
Biology, vol. 24, no. 1, pp. 442–453, 2004.
[217] S. Y. Jung, A. Malovannaya, J. Wei, B. W. O’Malley, and J.
Qin, “Proteomic analysis of steady-state nuclear hormone
receptor coactivator complexes,” Molecular Endocrinology,
vol. 19, no. 10, pp. 2451–2465, 2005.
[218] D. M. Lonard, R. B. Lanz, and B. W. O’Malley, “Nuclear
receptor coregulators and human disease,” Endocrine
Reviews, vol. 28, no. 5, pp. 575–587, 2007.